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 ABSTRACT 
The prevalence of type 2 diabetes mellitus has reached epidemic proportions worldwide. This 
complex disorder is characterized by defects in insulin secretion and insulin resistance. Type 
2 diabetes is a consequence of complex interactions among multiple genetic variants and 
environmental risk factors.  The genetic basis of type 2 diabetes is still poorly understood. 
The overarching aim of this study was to investigate various polymorphisms in Insulin 
receptor (INSR), leptin receptor (LEPR) and β3-adrenergic receptor (ADRB3) genes and 
evaluate their role in the incidence and progression of type 2 diabetes. Three single nucleotide 
polymorphisms (233, 234 and 276) in the exon 3 of INSR gene, a CTTTA pentanucleotide 
repeat Del/Ins polymorphism in the 3 UTR of LEPR gene and a single nucleotide 
polymorphism (Trp64Arg) in the ADRB3 gene were analysed. The study comprised of 500 
local subjects including 200 type 2 diabetes patients and 300 age and gender matched healthy 
controls. Restriction fragment length polymorphism and single stranded conformation 
polymorphism techniques were used for genotyping and the results were validated by direct 
sequencing assay. We observed that codon 233, 234 and 276 of INSR gene were 
monomorphic in our population thereby ruling out any possible association with type 2 
diabetes. However we found an association of LEPR and ADRB3 gene polymorphisms with 
risk factors and severity of type 2 diabetes, such as obesity, abnormal lipid profile, 
hypertension, elevated HbA1c levels and serum creatinine levels. The frequency of Del allele 
was 89.7% and 59.3% in cases and controls respectively (p<0.001; odds ratio 6.0; 95% 
confidence interval 3.61 - 9.97).  The wild allele (Del) in the LEPR gene showed a positive 
association with the disease as well as associated risk factors. The genotypes for Del/Ins 
polymorphism did not satisfy Hardy and Weinberg equilibrium (χ2=57.22). In ADRB3 gene, 
frequency of variant C (Arg) allele was observed to be 40% and 10.2% in cases and controls 
respectively (p<0.001; odds ratio 5.89; 95% confidence interval 3.69-9.39). Presence of C 
(Arg) allele was observed to be a risk factor, where as the wild T (Trp) allele exerted a 
protective effect against type 2 diabetes in our population. Presence of C allele was directly 
related to higher BMI, WHR, dyslipidemia and uncontrolled diabetes. Genotypes for 
Trp64Arg polymorphism were in Hardy and Weinberg equilibrium (χ2=0.48). The study 
signifies that Del allele in LEPR gene and Arg allele in ADRB3 are genotypic risk factors 
that confer susceptibility to type 2 Diabetes Mellitus in ethnic Kashmiri population. 
 INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a heterogeneous disorder characterized by two interrelated 
metabolic defects: insulin resistance coupled with impaired insulin secretion by β-cells in the 
pancreas (Kahn, 2008). An array of dysfunctions is associated with T2DM that are 
characterized by hyperglycemia and associated with microvascular, macrovascular and 
neuropathic complications. T2DM is regarded as a multifactorial disease with both a genetic 
component and an important non-genetic component(s) which undoubtly interacts in order to 
precipitate the diabetic phenotype (Beck et al., 1994). The number of people developing 
T2DM has increased rapidly in the last thirty years, at first in America and Europe, and more 
recently in Asia where it is said to be reaching epidemic proportions. Age, physical activity 
patterns, dietary habits, lifestyle and obesity play a crucial role in the modulation of the disease 
occurrence.   In the past few years, major advances relating to the genetic basis of T2DM have 
been made. This has cumulated in the discovery and confirmation of around twenty common 
predisposing loci (Lyssenko, 2009) but the variance in disease risk explained by these variants 
is much lower than predicted based on heritability studies. It follows that the genetic 
associations discovered to date represent the tip of the iceberg with respect to the genetic 
landscape of T2DM risk. In contrast to the genetic basis to T2DM, a great deal of robust 
evidence exists which documents the impact of lifestyle behaviors on the development of 
T2DM. Epidemiological studies have identified strong T2DM risk relationships for obesity, 
sedentary behaviours ( Hu et al., 2001, 2003; Dunstan et al., 2007) and diets rich in energy 
(Davis et al., 2009), processed carbohydrates (Hu et al., 2001) and animal fats (Winzell and 
Ahren, 2004). The strongest evidence comes from clinical trials, which show that intensive 
lifestyle interventions targeting weightloss through diet modification and physical activity have 
a major beneficial impact on diabetes incidence in high-risk individuals (Hammam et al., 2006; 
Lindstrom et al., 2006). The pattern of disease occurrence within and between populations that 
differ in their genetic and environmental reinforcement suggests that T2DM is caused by the 
interaction between adverse lifestyle behaviors and in part by the genetic profile of an 
individual. The predisposition to T2DM is thought to be conferred by a number of different 
genes that in isolation may have only minor effects, but in combination lead to the 
characteristic pathophysiological effects (Morton and Lio, 1997; McCarthy et al., 2002). This 
genetic susceptibility may be conferred by an unfavorable combination of individual 
polymorphisms in the genes involved, each one controlling part of the pathogenic process (De 
Meyts, 1997). These genes are defined as “diabetogenes” (Hoban et al., 1990; Taylor et al., 
 1990; Moller et al., 1996) many of which encode proteins of a functional complex that play a 
key role in glucose metabolism and others involved in the signal transduction characterizing 
insulin’s biological activity (Taylor et al., 2001). The investigation into the molecular 
mechanism for insulin action has clarified how insulin resistance is related to genetic factors 
and environmental factors (hyperglycemia, free fatty acids, inflammatory mechanism, etc.). 
Known genetic factors, include not only insulin receptor and insulin receptor substrate (IRS)-1 
gene polymorphisms that directly affect insulin signals but also polymorphisms of thrifty genes 
such as the β3-adrenergic receptor gene and the uncoupling protein (UCP) gene, associated 
with visceral obesity and promote insulin resistance. Glucolipotoxicity and inflammatory 
mediators are also important as the mechanisms for impaired insulin secretion and insulin 
signalling impairment. Recent attention has focused on the involvement of adipocyte-derived 
bioactive substances (adipokines) in insulin resistance. While TNF-α, leptin, resistin, and free 
fatty acids act to increase resistance, adiponectin improves resistance. Several single-
nucleotide polymorphisms (SNPs) have been described in these genes that have been 
associated with T2DM. Studies have investigated various SNPs associated with T2DM and 
found that among heterogeneous populations throughout the world, there are similar 
polymorphisms that convey genetic risks for T2DM in subgroups of main populations, i.e. 
Mexican Americans, Pima Indians, gypsies of southern Slovakia, African Americans, to name 
a few. This feature has been reported in cases of isolated ethnic groups (Gharbi et al., 2002; 
Vasarova and Hanson, 2003; Sánchez-Corona et al., 2004; Arfa et al., 2007; Knowler et al., 
2007) and among underprivileged groups in developed countries (Arroyo et al., 1999). 
Kashmir valley is a unique geographical area located in the north Indian state of Jammu and 
Kashmir. It differs from other areas in terms of its location, climate, amount of ultraviolet rays 
received, socio-demographic as well as lifestyle habits. The prevalence of T2DM in Kashmir 
valley was   6% in subjects aged ≥ 40 years (Zargar et al., 2000). In the young adults (20-40 
years), a prevalence rate of 2.4% was observed (Zargar et al., 2008). According to a recent 
hospital based retrospective study (Zargar et al., 2009), mortality trends among people with 
diabetes admitted to the tertiary care hospital (Sher-I-Kashmir Institute of Medical Sciences, 
Srinagar) were reviewed by screening the hospital records of all people with diabetes who died 
over the last nine years. Deaths associated with diabetes accounted for 7.11% (Zargar et al., 
2009). The mean age at death for people with diabetes was 60.07 years in men and 57.36 years 
in women. These studies show an increasing trend in the prevalence of the diabetes mellitus in 
Kashmir valley owing to increased susceptibility to the contributing factors of the disease and 
the changing lifestyle. However, apart from cross-sectional and retrospective studies, no 
 research has been done at genetic or molecular level to evaluate the causal genetic factors or 
polymorphic studies in key diabetogenes which would provide an insight to the susceptibility, 
control and treatment of the disease. In light of these observations this study is intended to 
evaluate various polymorphisms in key genes related to diabetes like Insulin receptor (INSR), 
Leptin receptor (LEPR) and β3-adrenergic receptor (ADRB3) genes: their prevalence, possible 
role in pathogenesis and correlation with risk factors. 
 
 REVIEW OF LITERATURE 
2.1. History of Diabetes Mellitus 
The first document known to mention descriptions of polyuric state resembling diabetes is an 
Egyptian papyrus dating from approximately 1500 BC. The term “diabetes” was first used by 
the Greek physician Aretaeus of Cappadocia in the 2nd century AD.  His writings contain a 
description that is accurate and clinical: “diabetes is an awful disease melting the body and 
limbs of the patient into urine. Life is short and painful and sooner rather than later the patient 
will expire” (Mogensen, 2011). During the same period, Galen, the Roman physician, spoke of 
two cases of a rare disease characterized by polyuria and polydipsia. Pre-Aretaeus there are 
hints of diabetes in certain hieroglyphs and in ancient accounts from India, where ants were 
drawn to sweet urine (almost a biological test for diabetes). In the 5th and 6th centuries, two 
notable Indian physicians, Susruta and Sharuka, described for the first time the association of 
polyuria with a sweet tasting substance in the urine (Fernandez, 2006). In the 17th century, 
Thomas Willis made several clever observations about the disease which still hold true today. 
He wrote that diabetes had been rare in classical times (Galen) “but in our age, given to good 
fellowship and gusling down chiefly of unllayed wine, we meet with examples and instances 
enough, I may say daily, of this disease..... As to what belongs the cure, it seems a most hard 
thing of this disease to draw propositions for curing, for this cause lies so deeply hid, and hath 
its origin so deep and remote”. Since then, plentiful efforts have been made to unravel the deep 
causes of this frequent disease. The idea that lifestyle contributes to the development of T2DM 
was proposed in France over a century ago by Étienne Lancereaux (1829-1910). He classified 
diabetes into diabète maigre (“lean diabetes”) and diabète gras (“fat diabetes”), equivalent to 
diabetes types 1 and 2. Increased affluence and decreased physical activity have since created a 
near-epidemic of T2DM, which began mainly in the post-war US, but spread worldwide to 
China, India, and Japan and many countries in the Middle and Far East (Mogensen, 2011). 
2.2. Definition and classification of Diabetes Mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycaemia (elevated 
levels of glucose in the blood) resulting from defects in insulin secretion, insulin action, or 
both. There are two major types of diabetes mellitus: type 1 and type 2 diabetes (Diabetes 
Care, 2004). Type 1 diabetes is an autoimmune disease that usually occurs in childhood but the 
onset may occur at any age; this type of diabetes results from a cellular-mediated autoimmune 
 destruction of the beta-cells in the pancreatic islets which usually leads to absolute insulin 
secretion deficiency. Type 2 diabetes on the other hand is a metabolic disorder that generally 
appears later in life but may occur in childhood and is characterized by the combination of 
insulin resistance and relative insulin secretion deficiency (Diagnosis and classification of 
diabetes mellitus, Diabetes Care, 2009). This type of diabetes usually begins predominantly 
with insulin resistance, which is a condition characterized by the inability of cells to respond to 
the action of insulin in transporting glucose from the bloodstream into muscle, fat, and liver 
cells (Lillioja et al., 1998). This condition causes a compensatory increase in the secretion of 
insulin from the pancreatic beta cells (hyperinsulinemia) in order to overcome the state of 
insulin resistance and thus help glucose enter the cells. However, in the long term, beta-cell 
mass and function progressively declines (Festa et al., 2006). The natural history of T2DM in 
many individuals involves years of insulin resistance balanced by elevated insulin secretion. 
The pivotal point is when the beta-cells begin to fail, and insulin production declines. Thus 
T2DM is characterized by both defects in insulin secretion and by cellular insulin resistance. 
Beside type 1 and type 2 diabetes there are several other classes of diabetes which are 
characterized by genetic defects of beta-cell function (Maturity Onset Diabetes of the Young: 
MODY1-6), transient neonatal diabetes, genetic defects in insulin action, disorders of the 
exocrine pancreas, endocrinopathies, drug- or chemical-induced diabetes, infections induced 
diabetes, uncommon forms of immune-mediated diabetes, and gestational diabetes mellitus 
(Diabetes Care, 2009). However, approximately 90–95% of all diabetes cases are T2DM 
(National Diabetes Fact Sheet, 2005). 
2.3. Diagnosis of type 2 Diabetes Mellitus 
T2DM is diagnosed using either repeat fasting or two hour plasma glucose concentrations 
following oral glucose challenge i.e. fasting blood glucose levels >126 mg/dl (>7.0 mmol/l) 
without symptoms, 2-hour glucose levels >200 mg/dl (>11.1 mmol/l) after an oral glucose 
tolerance test (OGTT) without symptoms, or random blood glucose levels >200 mg/dl [>11.1 
mmol/l] with symptoms (Diabetes Care, 2003). Because the progression from normoglycemia 
to hyperglycemia is slow and gradual, there are intermediate stages. These are defined as 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) where glucose values are 
considered to be above “normal” glucose tolerance but below those used to diagnose diabetes. 
As a result, many individuals have ‘intermediate hyperglycemia’ (WHO, 1999) sometimes 
referred as ‘impaired glucose regulation’, ‘prediabetes’ or, ‘non-diabetic hyperglycemia’ 
 (Forouhi et al., 2006). According to the criteria of World Health Organization (WHO, 1999) 
IFG and IGT are diagnosed when a person presents with fasting venous plasma glucose levels 
between 100–125 mg/dl (6.1 to 6.9 mmol/l) and 2-hour blood glucose level between 140–199 
mg/dl (7.8 –11.1 mmol/l) during a 75-g OGTT. In 2003, the American Diabetes Association 
(ADA) recommended that the IFG threshold should be lowered to 100 mg/dl (5.6 mmol/l) 
(Genuth et al., 2003). However, not all agencies, including WHO, have accepted this 
recommendation. 
The majority of those diagnosed with IFG and IGT (around 60%) do subsequently develop 
T2DM (Unwin et al., 2002). It is for this reason that IFG and IGT are commonly used to 
identify high-risk groups. For example, all-cause mortality rates in individuals with IFG or IGT 
are almost twice those of persons with normal glucose levels (Saydah et al., 2001), justifying 
early intervention. Although the etiology of T2DM has not been established in full, a number 
of risk factors are well defined. According to the ADA (Screening for type 2 diabetes: Diabetes 
Care 2004), the risk of developing T2DM is associated with age (increased risk at ≥45 years), 
overweight/obesity, and lack of physical activity (PA). T2DM is more common in individuals 
with a family history of the disease, in certain ethnic groups (e.g. African-Americans, 
Hispanic-Americans, Native Americans, Asian-Americans, and Pacific Islanders), and in 
individuals with hypertension (≥140/90 mmHg in adults), dyslipidaemia (HDL cholesterol ≤35 
mg/dl [0.90 mmol/l] and/or a triglyceride level ≥250 mg/dl [2.82 mmol/l]), IFG, IGT, a history 
of vascular disease or gestational diabetes, or polycystic ovary syndrome. In addition, a range 
of common genetic variants are also known to raise the risk of T2DM (Lyssenko et al., 2005; 
2008; Zeggini et al., 2008), of which some may interact with lifestyle factors to modify the risk 
of the disease (Franks et al., 2007). 
2.4. Epidemiology of type 2 Diabetes Mellitus  
2.4.1 The global burden of type 2 Diabetes Mellitus 
Over recent decades, the progressively increasing global prevalence of T2DM (Zimmet, 1999) 
has created a major public health challenge. This is because T2DM is a major cause of 
premature morbidity and mortality, and as such it imposes a heavy burden on affected 
individuals and society as a whole. Furthermore, the disease is associated with long-term 
microvascular and macrovascular injury, such as retinopathy (eye disease), nephropathy 
(kidney disease), neuropathy (damaged nerves), peripheral vascular disease, cerebrovascular 
disease (including hemorrhagic stroke), and atherosclerotic disease (Report of the expert 
 committee on the diagnosis and classification of diabetes mellitus (WHO, 1999; Diabetes Care, 
2003). Mortality rates in adults with T2DM are 2-4 folds higher than those observed in non-
diabetic individuals, with many premature deaths in people with diabetes being attributable to 
cardiovascular disease (CVD) (Haffner et al., 1998; Fox et al., 2007). According to the WHO, 
the number of people with diabetes of all ages worldwide increased from 30 million to 171 
million between 1985 and 2000 (WHO, 2006). These numbers are expected to increase to 366 
million in 2030. The estimated prevalence of diabetes approximated 2.8% in 2000 and is 
predicted to be around 5.8% in 2030 (Wild et al., 2004). In Sweden, it is estimated that 
diabetes affects ~350,000 people (2.2–4.5% of the population) (Berger et al., 1998; Eliasson et 
al., 2002; Jansson et al., 2007). Costs incurred from diabetes complications make up 1.6–6.6% 
of total health care spending in eight European countries, including Sweden (~5%) (Jonsson, 
2002). 
WHO estimates that between 2000 and 2030 the most striking increase in T2DM prevalence 
will be among persons aged 65 years and older. By 2030, it is estimated that more than 48 and 
82 million older adults (>65 yrs) in developed and developing countries, respectively, will be 
afflicted with T2DM (Wild et al., 2004). The DECODE Study Group, which is comprised of 
nine European countries (including Sweden) estimates that the prevalence of T2DM will be 
<10% in persons younger than 60 years of age and 10–20% in persons aged 60–79 years 
(Diabetes Care, 2003). The reason for this shift in the demographic distribution of affected 
individuals is threefold: firstly, global populations are aging; secondly the complications of 
T2DM can be treated more efficiently than ever before, which means that people are living 
longer with diabetes; and thirdly, lifestyle behaviours that increase diabetes risk are becoming 
more common in all age groups (Colagiuri et al., 2005; Hussain et al., 2007). 
The “Top 10” countries in the world, in terms of the number of people with diabetes, for 2011 
and 2030, are shown in Table 1. At both time points, the three countries with the largest 
number of people with diabetes are China, India and United States. 
India is one of the leading countries in the world with largest number of diabetic subjects 
earning the dubious distinction of being termed the “diabetes capital of the world”. Nowhere is 
the diabetes epidemic more pronounced than in India as the World Health Organization 
(WHO) reports show that 32 million people had diabetes in the year 2000 (Wild et al., 2004). 
The International Diabetes Federation (IDF) estimates the total number of diabetic subjects to 
be around 61 million in India and this is further set to rise to 100 million by the year 2030. 
Other “hot spots” for diabetes include the Gulf region in the Middle East, another area where 
the epidemic is taking hold (Qiao et al., 2004).  
 2.4.2 Type 2 Diabetes Mellitus in Kashmir valley 
Major differences in the prevalence rates of Diabetes Mellitus have been observed in migrant 
Indians in different countries and even in different parts of India (Ramiya et al., 1990). Most of 
the studies consider Indians as one homogenous group, which is inappropriate. Indians differ in 
ethnicity, religion, place of origin (different parts of India) and diet. The Valley of Kashmir lies 
in the northern region of the Indian subcontinent, in the state of Jammu and Kashmir. The 
population is predominantly Muslim and of uniform ethnicity. A cross-sectional population 
survey was undertaken to determine the prevalence of T2DM and impaired glucose tolerance 
in subjects aged 40 years or more in Kashmir Valley (Zargar et al., 2001). 6091 subjects aged 
40 years or older were randomly selected. Abnormalities of carbohydrate intolerance were 
determined as recommended by WHO. 12.34% subjects had an abnormal Glucose tolerance 
test (GTT), 8.09% were having impaired glucose tolerance (IGT) and 4.25% suffered from 
undiagnosed diabetes mellitus. The prevalence of IGT as well as of diabetes was significantly 
more in females as compared to males (P<0.001) (Zargar et al., 2001). Prevalence of known 
diabetes as well as that of abnormal GTT steadily increased with age. Subjects with diabetes on 
GTT had a higher waist: hip ratio. Obese subjects showed significantly higher basal as well as 
2 hr blood glucose. The prevalence of diabetes as well as IGT was significantly higher in the 
urban population. The study concluded that 1.89% of the general population had known 
diabetes, 4.25% had undiagnosed diabetes and 8.09% had impaired glucose tolerance test; 
making the total load of abnormal glucose tolerance 14.23% in Kashmir Valley. In subjects 
greater than 40 years of age having a family history of diabetes, obesity, higher age (50 years 
or above), female sex, and urban origin had more chances of developing abnormal glucose 
tolerance (Zaragar et al., 2001).  In another study the burden of T2DM and other abnormalities 
of glucose tolerance were assessed in young-adult (20-40 years) men and non-pregnant women 
in 3032 subjects from Kashmir Valley (Zargar et al., 2008). The study included a 
questionnaire, anthropological measurements, blood sampling, and a standard OGTT. Out of 
3024 subjects screened, prevalence of diabetes, impaired glucose tolerance (IGT), and 
impaired fasting glycemia [IFG, World Health Organization Geneva, 1999], IFG [American 
Diabetes Association, 2004] was 2.5%, 2.0%, 11.9% and 26.7%, respectively. Overall, age-
adjusted prevalence of T2DM (known plus unknown), IGT, IFG (WHO) and IFG (ADA) was 
2.4%, 1.6%, 11.1% and 25.2% respectively (Zargar et al., 2008). According to this study the 
difference in diabetes prevalence was significant by age, habitat, family history of diabetes and 
BMI. The ratio of known-to-unknown diabetes was 1:10. 
 Table 1: Top 10 countries for estimated numbers of adults with diabetes, 2011   and 
2030 
Rank Country/Territory 2011 
(Millions) 
Country/Territo
ry 
2030 
(Millions) 
1 China 90.0 China 129.7 
2 India  61.3 India 101.2 
3 United States 23.7 United States 29.6 
4 Russian Federation 12.6 Brazil  19.6 
5 Brazil 12.4 Bangladesh 16.8 
6 Japan 10.7 Mexico 16.4 
7 Mexico 10.3 Russian 
Federation 
14.1 
8 Bangladesh 8.4 Egypt   12.4 
9 Egypt 7.3 Indonesia 11.8 
10 Indonesia  7.3 Pakistan 11.4 
              (Courtesy: International diabetes federation, 2011) 
 2.4.3 Type 2 Diabetes in children–the emerging threat 
There is now a major emerging global phenomenon that reveals a new perspective of the global 
diabetes epidemic. This is the younger age of onset being seen in T2DM, which was formerly 
considered a disease of adults (Zimmet et al., 2001). However, in recent years, T2DM is 
appearing at a younger age, not only in the young adult population, but also in adolescents and, 
occasionally, in children (Zimmet et al., 2001; Shaw et al., 2008). Although T2DM has 
traditionally been considered a disease of adult onset, in the past decade T2DM incidence has 
increased rapidly in the young; in some aboriginal groups such as Pima Indians, T2DM is as 
common in children as it is middle-aged adults of lower risk ethnic groups (Franks et al., 
2006). The explanations for the rising trends in paediatric T2DM are likely to be attributable to 
changing lifestyles and the high prevalence of obesity in contemporary children (Wiegand et 
al., 2004; Singh et al., 2004). Data on T2DM incidence in European children are scarce. 
Nevertheless, the proportion of children of European descent diagnosed with T2DM appears to 
remain low.  
T2DM has already been reported in children from Japan and other Asian nations, the USA, the 
Pacific Islands, Hong Kong, Australia, and the United Kingdom (Zimmet et al., 2001). A 
French study (Ortega et al., 2001) indicated a relatively low, but increasing, number of 
children with glucose levels exceeding the thresholds for T2DM and an Austrian population-
based study (Rami et al., 2003) reported an incidence of 0.25/100,000/year. In the U.K., the 
incidence of T2DM was substantially higher in children from ethnic minority groups: 3.9 and 
1.25/100,000/year for children of African and South Asian origin, respectively, compared to 
0.35/100,000/year in ethnically European children (Haines et al., 2007).  In Japan, T2DM 
accounts for 80 percent of cases of diabetes in childhood in that country (Kitagawa et al., 
1998). This is certainly an emerging public health problem of significant proportions as the fall 
in the age of onset of T2DM is an important factor influencing the future burden of the disease. 
Onset in childhood heralds many years of disease and an accumulation of the full range of both 
micro- and macrovascular complications particularly as compliance to hypoglycemic 
medications is often an issue (Dabelea et al., 1999). The risk determinants for T2DM in 
children and adolescents are similar to those seen in adults, with obesity almost always being 
present (Alberti et al., 2004). In-utero exposure to hyperglycemia now appears to be an 
additional risk factor to having a family history of diabetes and suggests that better 
management of diabetes in pregnancy and prevention of gestational diabetes may reduce the 
risk of diabetes developing in the offspring (Pettitt et al., 1988). 
 2.5. Pathophysiology of type 2 Diabetes Mellitus 
2.5.1 Regulation of insulin secretion 
Insulin is secreted by pancreatic β-cells in response to elevated blood glucose. Glucose is taken 
into the β-cells via high capacity facilitated insulin-independant glucose transporter 2 (GLUT 
2). Intracellular glucose is phosphorylated by glucokinase, and glucose-6-phosphate is 
metabolized in the mitochondria, resulting in an increase of ATP/ADP ratio, and the closure of 
ATP-sensitive potassium channels (KATP).  An increase in intracellular potassium (K+) 
concentration leads to the depolarization of the cell membrane, and voltage –sensitive calcium 
(Ca2+) are opened. Influx of Ca2+ into the β-cells triggers the translocation and exocytosis of 
insulin granules (Barg, 2003). Glucose stimulated insulin secretion is biphasic. The first 5-10 
minutes is a rapid phase, followed by a prolonged phase as long as glucose stimulation persists 
(Del Prato et al., 2002). Insulin secretion is influenced by a variety of other factors. Nutrients 
and metabolites, e.g. FFAs, amino acids, ketone bodies, as well as incretins, such as glucose 
dependant insulinotropic polypeptide and glucagon-like polypeptide-1 are well known 
regulators of the first-phase insulin secretion  (Henquin and Meissner, 1986; Haber et al., 2003; 
Vilsbøll and Holst, 2004). Pancreatic hormones and peptides such as insulin and C-peptide, 
glucagon and pancreastatin regulate insulin secretion in paracrine and intra-islet endocrine 
manner (Leibiger et al., 1998). Other hormones (e.g. growth hormone, cortisol, epinephrine, 
thyroid hormones) also play an important role in the regulation of insulin secretion. Pancreatic 
islets are rich in autonomic nerves, and sympathetic neuro-mediators inhibit insulin secretion, 
whereas parasympathetic stimulation leads to an increase of insulin secretion (Kiba, 2004). 
Leptin inhibits insulin secretion by the activation of KATP channels (Kieffer et al., 1997).  
2.5.2 Insulin resistance and type 2 Diabetes Mellitus 
T2DM is said to be a “2-hit” disease in which Insulin Resistance (IR) is accompanied by β-cell 
defects preventing the compensatory upregulation of insulin secretion (Bergman et al., 2002). 
The genetic and molecular bases for the reduction in insulin sensitivity and β-cell function are 
not fully understood, but it seems that body fat distribution and especially visceral fat are major 
determinants of IR while reductions in β-cell mass contribute to β-cell dysfunction (Kahn, 
2003). Hitherto, T2DM had been attributed solely to the development and worsening of IR 
(Donath and Halban, 2004). Reduced glucose metabolism due to sedentary lifestyles, increased 
glucose availability due to overfeeding, and progressive reduction in glucose storage as insulin-
sensitive tissues “resist” plasma glucose transport were presumed to worsen glycemia and lead 
 to T2DM (Gerich, 1999; Donath and Halban, 2004). A number of clinical data points support 
IR as a critically important etiologic factor in type 2 diabetes: (1) T2DM and IR are highly 
correlated; more than 80% of individuals with T2DM also manifest IR (Gerich, 1999). IR is 
also common in obese individuals who have not yet developed T2DM (Balkau et al., 2002). IR 
may thus provide the pathophysiologic linkage between increasing weight and increasing 
glycemia. (2) IR appears to precede (is detectable earlier than) beta-cell dysfunction in the 
pathogenesis of type 2 diabetes (Gerich, 1999).(3) IR appears to cause beta-cell dysfunction via 
the mechanism of beta-cell exhaustion; i.e.,  increased secretory demand, due to peripheral 
tissue resistance to insulin signalling, results in continual beta-cell hyperstimulation and 
eventual failure (Kahn, 2001; Leahy, 2005). While T2DM is indeed highly correlated with IR, 
what requires explanation—if IR is indeed causative—is the absence of correlation between IR 
and T2DM. Prevalence rates of IR in various populations are often far greater than those of 
T2DM; clearly, large majorities of individuals with IR do not go on to develop the disease 
(Porte and Kahn, 1995; Bonora et al., 1998; Weyer et al., 1999; Zavaroni et al., 1999; 
DeFronzo, 2004). Temporal priority of IR in the pathogenesis of T2DM has been disputed by a 
number of studies wherein beta-cell function has been carefully assessed and potentially 
confounding factors, such as obesity and adipose tissue distribution, accounted for (Pimenta et 
al., 1995; Gerich, 1999). Not only may beta-cell dysfunction pathogenically precede IR, but 
there is also some evidence that the former may contribute to the latter. For example, loss of 
pulsatile insulin release, a beta-cell secretory dysfunction characteristic of type 2 diabetes, has 
been associated with the development of IR (Matthews et al., 1983; Kahn, 2001). To consider 
IR as causative of beta-cell dysfunction, and thus of T2DM, seems counterintuitive if only 
because so many individuals with IR do not develop the disease (Weyer et al., 1999; Leahy, 
2005). Studies seeking to distinguish carefully between the relative contributions of IR and 
insulin secretory deficits to T2DM (both pathogenesis and pathophysiology) suggest that IR is 
neither a necessary nor a sufficient condition (Nesher et al., 1987; Arner et al., 1991; Byrne et 
al., 1996). The key defect, in both lean and obese individuals with diabetes, is impaired insulin 
secretion. By contrast, lean patients with T2DM were not insulin resistant, and obese controls, 
while insulin resistant, did not have diabetes because their insulin secretory capacity was 
sufficient to maintain gluco-homeostasis (Nesher et al., 1987). 
 
 
 2.5.3 Beta-cell dysfunction as primary defect 
While not the primary cause of T2DM, IR remains an important treatment target; it is itself a 
risk factor for atherosclerosis and cardiovascular disease and, if untreated, promotes 
hyperglycemia and the glucotoxic environment to which beta-cells in susceptible individuals 
may be particularly vulnerable (Buchanan et al., 2002; Bertoni et al., 2007; Abbasi et al., 
2008). Nevertheless, a consensus of investigators and clinicians have determined that beta-cell 
dysfunction, commonly but not necessarily occurring in a subset of individuals with IR, is 
primarily responsible (both a necessary and sufficient condition) for T2DM. A functional beta-
cell can compensate for IR indefinitely, perhaps for the lifetime of the individual; progressive 
loss of betacell function, on the other hand, is crucial to the development of T2DM and to the 
worsening of hyperglycemia even under treatment (Porte and Kahn, 1995; Del Prato et al., 
2007; Bonora et al., 2008; Lencioni et al., 2008). Loss of beta-cell function is likely to be 
accompanied by reduction in beta-cell mass. Autopsy studies have confirmed that functional 
decrements are associated with such reductions. Beta-cell apoptosis begins early in the disease 
process and at diagnosis between 40% and 60% of normal beta-cell volume may already have 
been lost (Butler et al., 2003). 
2.5.4 Mechanisms of beta-cell dysfunction 
Contenders for the sources of beta-cell dysfunction include glucotoxicity, which may mean 
nothing more, at least initially, than that genetically susceptible beta-cells are extremely 
sensitive to even modestly elevated glucose levels. For these beta-cells, chronic glucose 
elevations even slightly above the normal range inaugurate a toxic environment characterized 
by deleterious changes in function, mass, and phenotype. Worsening beta-cell response then 
exacerbates the glucotoxic environment, which worsens beta-cell response in a vicious spiral of 
deterioration. Acute phase insulin response is lost; a number of stress response processes are 
activated, indicating an increase in cellular stress; and an upregulation of apoptotic genes has 
been noted (Weir and Bonner, 2004). Lipotoxicity associated with elevated levels of free fatty 
acids—commonly observed in the obese, the insulin resistant, and individuals with T2DM — 
has been linked to decreased insulin synthesis and increased metabolic stress in beta-cells 
(Standl, 2007; Poitout and Robertson, 2008). Human amyloid, expressed as islet amyloid 
polypeptide, is cytotoxic (Janson et al., 1999). Amyloid deposition in beta-cells is a 
characteristic histopathology of T2DM, and has been observed in up to 90% of patients 
(Lencioni et al., 2008; Finegood and Topp, 2001). Severity of amyloidosis correlates with 
 duration and severity of diabetes (Lorenzo et al., 1994; Hayden and Tyagi, 2002; Hoppener 
and Lips, 2006; Lencioni et al., 2008). 
2.6 Causes of the rise in prevalence of diabetes 
2.6.1. Genetic predisposition 
Several studies on migrant Indians across the globe have shown that Asian Indians have an 
increased risk for developing T2DM and related metabolic abnormalities compared to other 
ethnic groups (Mohan et al., 1986; McKeigue et al., 1991; Abate and Chandalia, 2001). 
Although the exact reasons are still not clear, certain unique clinical and biochemical 
characteristics of this ethnic group collectively called as the “Asian Indian phenotype” is 
considered to be one of the major factors contributing to the increased predilection towards 
diabetes (Joshi, 2003; Deepa et al., 2006). Despite having lower prevalence of obesity as 
defined by body mass index (BMI), Asian Indians tend to have greater waist circumference and 
waist to hip ratios (Ramachandran et al., 1997) thus having a greater degree of central obesity. 
Again, Asian Indians have more total abdominal and visceral fat for any given BMI (Raji et al., 
2001) and for any given body fat they have increased insulin resistance (Chandalia et al., 
1999). Moreover, they have lower levels of the protective adipokine-adiponectin and have 
increased levels of adipose tissue metabolites (Abate et al., 2004). Studies on neonates 
suggested that Indian babies are born smaller but relatively fatter compared to Caucasian 
babies and are referred to as “the thin fat Indian baby” (Yajnik, 2002; Yajnik et al., 2003). 
Another study confirmed this finding and suggested that the “thin fat phenotype” in neonates 
persisted in childhood and could be a forerunner of the diabetogenic adult phenotype 
(Krishnaveni et al., 2005). These findings suggest that Asian Indians are more prone to 
diabetes and related metabolic abnormalities. Genetic factors that determine body fat 
distribution and glucose metabolism have to be fully elucidated for the better understanding of 
the biochemical and molecular mechanisms behind the etiopathogenesis of diabetes. Studies 
have shown that while some genes seem to confer increased susceptibility to diabetes in 
Indians (Abate et al., 2005; Vimaleswaran et al., 2005), some protective genes in Europeans do 
not appear to protect Indians (Radha et al., 2006).  
2.6.2 Inherited factors in type 2 Diabetes Mellitus 
Heritability estimates provide an indication of the extent to which genetic and environmental 
factors influence the variance of specific traits (phenotypes) within populations. Heritability is 
 formally defined as a ratio of variances, specifically as the proportion of total variance in a 
population for a particular measurement, taken at a particular time or age that is attributable to 
variation in additive genetic or total genetic values, termed narrow-sense heritability (h2) and 
broad-sense heritability (H2), respectively (Visscher et al., 2008). The H2 for T2DM ranges 
from 26% to 75% (Kaprio et al., 1992; Poulsen et al., 1999; Barroso, 2005). The offspring risk 
ratio is often used to express the heritable risk of developing a disease. In the Framingham 
Offspring Study the RR in offspring with one diabetic parent was ~3.5, and when both parents 
had diabetes the risk ratio (RR) increased to ~6.0, compared with the risk in offspring of non-
diabetic parents (Meigs et al., 2000). The heritable risk of diabetes extends beyond the 
influence of the parents to other family members. In the Framingham study, a history of 
diabetes in any biologic ancestral family member or sibling independently and progressively 
increased diabetes risk in the proband. Multiple studies of twins also provide compelling 
evidence for a genetic component for T2DM. Estimates for concordance rates range from 0.29 
to 1.00 in monozygotic (MZ) twins, while in dizygotic (DZ) twins the range was 0.10– 0.43 
(Gottlieb and Root, 1968; Barnett et al., 1981; Newman et al., 1987; Kaprio et al., 1992; 
Poulsen et al., 1999; Medici et al., 1999). Lastly, the high levels of heritability for insulin 
sensitivity and insulin secretion also supports a genetic component to diabetes (Gerich, 1998; 
Elbein et al., 1999; Elbein et al., 2000). 
2.6.3 Ethnicity 
Evidence for a genetic component of T2DM comes in part from ethnic-specific differences in 
prevalence rates for T2DM, which range from 1% in Chile Mapuche Indian, 2% among 
Caucasians in Europe, to frequencies as high as 41% in the Nauru (Pacific Island) and 50% 
among Pima Indians in Arizona (Diamond, 2003). A 2004–2006 U.S. national survey 
including people aged 20 years or older indicated that 11.8% of African-Americans, 10.4% of 
Hispanics-Americans, 7.5% of Asian- Americans, and 6.6% of non-Hispanic whites Americans 
had clinically manifest diabetes. Among Hispanics, rates were 12.6% for Puerto Rican 
Americans, 11.9% for Mexican Americans, and 8.2% for Cuban Americans (CDC, 2008). All 
these findings are age-adjusted. Ethnic variability can be partially attributed to non-genetic 
environmental and cultural factors. However, some studies show that diabetes prevalence 
differs markedly across ethnic groups, even when environmental exposures are similar. For 
example, Asians living in the UK have a prevalence of diabetes 3.8-fold higher than that in 
whites in the UK (Mather and Keen, 1985). According to the WHO, between 2000 and 2030, 
 Asia and Africa are likely to experience a 2–3-fold increased prevalence of T2DM (Wild et al., 
2004). The organisation further predicts that the most new cases of T2DM will emerge from 
India, China, and the USA, partly because these countries have some of the world’s largest 
populations, but also because these are ethnically at risk populations that are rapidly adopting 
obesogenic lifestyles. According to the WHO, Bangladesh, Brazil, Indonesia, Japan, and 
Pakistan will also be heavily burdened by T2DM in the future.  
2.7 Genetic Studies associated with type 2 Diabetes Mellitus 
In 2001, the draft sequence of the human nuclear genome was published (Lander et al., 2001; 
Venter et al., 2001). The human genome consists of approximately 2.85 billion base pairs 
encoding about 20,000–25,000 genes. Although 99.9% of the human DNA sequence is thought 
to be identical between unrelated individuals, about 0.1% of coded DNA differs between the 
two chromosomal strands at the same base (Kruglyak and Nickerson, 2001). It is these 
differences that account for the diversity in human phenotypes and their responsiveness to 
environmental exposures including, but by no means limited to, diet and physical activity. 
DNA variation occurs in several known forms. Sequence variations occurring in less than 1% 
of the population are defined as mutations whereas more common variants are defined as 
polymorphisms (Strachan and Reed, 1999). SNPs are the most commonly studied form of 
genetic variant. Other well known polymorphisms are variable number of tandem repeats 
(VNTRs) that include mini-satellites (repeat sequences of several nucleotides) that tend to 
cluster near ends of chromosomes and microsatellites (usually as di-, tri-, and tetra-nucleotide 
repeats) that are distributed throughout the genome (Strachan and Reed, 1999), inversions, 
insertions, deletions, copy number variants (CNVs), and other complex rearrangements (Feuk 
et al., 2006). 
Polymorphisms are thought to occur because of selective pressures or randomly (genetic drift). 
Random variations eventually disappear as the contributing alleles become either fixed or 
extinct. Irrespective of the specific type of polymorphism, there is a plethora of common DNA 
sequence variants that can (and have) been used as disease predisposing markers in human 
population-based studies. Although many bona fide examples of disease associated 
polymorphisms have been identified, by and large, these are non-functional variants, which 
merely ‘tag’ the (often) unobserved causal variant. Approximately 12 million SNPs have been 
identified (Sachidanandam et al., 2001). More than 90% of the genomic variability between 
individuals is thought to be attributable to SNPs (Palmer and Cardon, 2005). The majority of 
 these SNPs are biallelic and can be transition (purine-purine A↔G or pyramidine-pyramidine 
C↔T) or transversion (purinepyramidine or pyramidine-purine) substitutions (Kimura, 1980). 
Approximately two thirds of SNPs are transition substitutions between double ring structured 
purines (A↔G) or between single ring structured pyrimidines (T↔C), whereas one third of 
SNPs are transversion substitutions between a purine and a pyrimidine nucleotide (Guo and 
Jamison, 2005). The classification of SNPs is dependent on their genomic location. Coding 
SNPs (cSNP) are located in exons. Individual exons may contain coding DNA and/or non-
coding DNA (untranslated sequences) and may be either synonymous or non-synonymous 
(Burton et al., 2005). Synonymous SNPs are typically silent and alter the DNA sequence, but 
do not change the amino acid coding sequence. Non-synonymous cSNPs alter the DNA 
sequence in a coding region such that the amino acid coding sequence of the protein is 
changed. These cSNPs are prioritized as genetic markers because a change in the amino acid 
structure and function may impact the formation of the target protein. The majority of SNPs 
are located in the non-coding region of the genome (Strachan and Read, 1999). However, some 
of these intronic SNPs have no known function but may play a regulatory role in modulating 
gene expression of coding regions. These SNPs are termed regulatory or rSNPs. rSNPs located 
in the promoter region may affect transcription factor sites and rSNPs located in the 5 UTR 
and 3  UTR (untranslated regions) may also affect protein-binding sites by changing sequence 
motifs. rSNPs may still have consequences for gene splicing, transcription factor binding, or 
the sequence of non-coding RNA. Intronic SNPs and intergenic SNPs (regions between genes) 
lie in the non-coding regions. It is generally thought that non-synonymous SNPs in a coding 
sequence are more likely to affect the function or availability of a protein than other SNP 
classes (Carlson et al., 2004). However, all SNP types can cause disease, for example by 
altering the regulation of transcription of a critical protein. The true distribution of disease 
associated variants between non-coding and coding sequences is unknown (Carlson et al., 
2004). 
There are at least six established ways in which SNP genotyping might help advance our 
understanding of the molecular basis to human disease (Schork et al., 2000; Palmer et al., 
2005). These include:  
 1) Hypothesis-free gene discovery and mapping 
 2) Association-based candidate polymorphism testing 
 3) Diagnostics and risk profiling 
 4) Prediction of response to environmental stimuli 
 5) Pharmacogenetics 
  6) Homogeneity testing and epidemiological study design 
2.7.1 Different types of polymorphic studies on type 2 diabetes          
The most common polymorphism in the human genome and which has been most extensively 
used in genetic studies is the single-nucleotide polymorphism. Polymorphisms are 
terminologically distinguished from mutations by a frequency criterion meaning that different 
forms of the polymorphism termed alleles are observed more often in the general population 
than mutations, with a population frequency of < 1% often used as a cut-off value. Currently, 
more than 9 million SNP are described in databases. SNPs occur on average once every 200 
base pairs in the human genome, many of those however being very rare (Crawford and 
Nickerson, 2005). Currently, the modest effect sizes of the known T2DM susceptibility 
variants limit their use, individually or in combination, in the prediction of disease risk (Lango 
et al., 2008). It is not yet known how many the epigenetic effects, such as the maternal uterine 
environment impact on the risk of diabetes in the offsprings and thus inflates the estimates of 
heritability (Dabalea and Pettitt, 2001). In addition, not only the SNPs used in most studies but 
also the copy number variants in genome may associate with risk of T2DM. Gene-gene 
interactions and gene-environmental interactions could be contributory factors in the 
difficulties in finding T2DM genes (McCarthy and Zeggini, 2009). Three aspects on the study 
of T2DM genes are presented in the following paragraphs. 
Linkage scans 
In typical genetic linkage studies, correlations between inheritance of a trait and chromosomal 
regions within family units, such as sibling pairs or multigenerational pedigrees, are 
investigated. Linkage studies have had some success in identifying the molecular basis of 
monogenic diseases, but fewer successes with common, more complex phenotypes, such as 
T2DM or atherosclerosis (Hegele, 2002). In the late 1980 and 1990s, genome mapping 
provided genome wide collections of markers and technologies for typing linkages in hundreds 
of individuals. Multiple genome wide linkage scans for type 2 diabetes have been done, but no 
single region in the genome has been widely replicated in these studies. Recently, a large study 
combining 83 linkage reports was published and it provided some evidence that there might be 
major genes for type 2 diabetes in chromosomal locations 6q, 1q,1p, 2q, 20q, 17pq, 8p, 19q 
and 9q (Lillioja and Wilton, 2009). However, there has been no clear path for progressing from 
linkage to gene identification (Florez et al., 2003). Studies are variable between populations. If 
only a subset of type 2 susceptibility genes is required for the disease and the frequencies of 
 these genes differ between populations, the results are variable. When the risk allele is present 
at a high frequency and has only a modest impact, linkage suffers a loss of power. This is 
because allele sharing of used markers is only observed if the risk allele is inherited from only 
one side of the pedigree (Florez et al., 2003.) 
Candidate gene studies 
Candidate genes, either positional or functional, can be studied by linkage based methods or 
association studies. The typical association study is a case-control study, where the difference 
in allele frequency of candidate gene polymorphisms is examined between affected individuals 
and unrelated controls, for example between type 2 diabetes patients and healthy individuals. 
There are three possible explanations for a positive association between disease and allele. 
First, there might be a true association so that the gene variant actually has a causative role in 
the development of the disease. Second, the positive association can arise if the marker studied 
is in linkage disequilibrium with another truly causal locus. Linkage disequilibrium takes 
place, when two genetic markers occur together more frequently than would be expected from 
random association. This means that marker allele is so close to the other allele that these 
alleles are inherited together over many generations. This can happen because of a variety of 
reasons, including recent admixture of populations with different allele frequencies, selection 
in favour of a specific allele, genetic drift or population bottlenecks or new mutations (Weeks 
and Lathrop, 1995.) The linkage disequilibrium between alleles can be measured with some 
parameters. D is the most common measure, and can be calculated as PAB − PA × PB, where 
PA is a frequency of allele A in the first loci and PB the frequency of allele B in the second 
loci. The value of D is dependent on allele frequencies, but another measure r2 is the 
correlation of alleles at the two sites, and is formed by dividing D2 by the product of the four 
allele frequencies at the two loci. The case of r2 = 1 is known as perfect LD. In perfect LD, 
observations at one marker provide complete information about the other marker (Ardlie et al., 
2002.) Selection bias or another bias can also lead to false positive association. For instance, 
some population substrata may be more susceptible to develop T2DM because of an 
unmeasured factor, such as ethnicity or genetic background, for which the genotype is merely 
an indirect marker (Hegele, 2002). Therefore, genetic isolates, such as Finns with a history of a 
small founder population, long-lasting isolation and population bottlenecks represent 
exceptional resources in the identification of disease genes. It can also be assumed that the vast 
majority of cases are caused by the same mutation, and disease alleles reveal linkage 
disequilibrium (LD) with markers over significant genetic intervals compared to older 
populations (Peltonen, 2000.)  
 Candidate gene studies have had disappointing outcomes in the field of T2DM. Many studies 
have been limited in power; the small sample sizes are inadequate to detect the kinds of effects 
that are known to be realistic in complex traits. It might also be that the candidate genes are 
selected on the basis of limited knowledge of the etiology of the disease. In addition, there 
might have been a poor understanding of the architecture of genetic variation. The genotyping 
methods have been time-consuming and also the irreproducibility of results may have been 
further reinforced by liberal thresholds for defining significance and the tendency to over-
interpret the results (McCarthy and Zeggini, 2009.) 
Genome wide association studies 
Over the last few years, genome-wide association studies (GWAS) have been extremely 
successful in the detection of loci for complex disease traits such as obesity and T2DM. The 
GWAS method involves testing associations with disease traits for a large number of genetic 
markers (usually more than 1,000,000 SNPs) over the whole genome. The method differs from 
the traditional biologic candidate gene approach, in that no specific hypothesis is tested; the 
approach instead relies heavily on replication of association signals across multiple populations 
and generally requires very large sample sizes to overcome the problems (related mainly to 
diminished power) inherent in conducting so many association tests (Hardy and Singleton, 
2009). This finding highlights the relative importance of inherited defects in insulin secretion 
on beta-cells rather than insulin resistance in the etiology of T2DM (Florez, 2008; Prokopenko 
et al., 2008). With the commercially available chips, a very large number of SNPs (105 -106) 
in the genome can nowadays be detected from an individual (Grant and Hakonarson, 2008). At 
least 30 GWA scans for T2DM have been performed (McCarthy and Zeggini, 2009). GWAs 
have proved to be successful in identifying susceptibility variants, but the power of individual 
studies to detect small or modest effects at common SNPs has been limited (McCarthy and 
Zeggini, 2009). It is very disconcerting that the GWA studies and linkage studies detect 
different genes; GWA studies may detect genes that linkage studies have been insufficiently 
powered to detect but linkage studies may identify genes that have multiple variants within the 
same gene and variants rare enough individually will be undetected by current GWA studies 
(Lillioja and Wilton,  2009). Continuous efforts through GWA meta-analysis and fine mapping 
may represent the way to explain the “missing heritability” of T2DM, since it is claimed that 
about 20 known variants explain only 5–10% of the inherited predisposition of T2DM 
(McCarthy and Zeggini, 2009).  
 
 2.8 Review of literature on candidate genes of the present study 
2.8.1 Insulin Receptor (INSR) gene 
The insulin receptor is a complex multifunctional protein subserving various biological effects. 
The receptor's organizational structure was firmly established, based largely on the amino acid 
sequence deduced after cloning of the insulin receptor cDNA (Ebina et al., 1985; Ullrich et 
al.1985). Subsequently it was shown that the cDNA was derived from a gene composed of 22 
exons located on chromosome 19 (Seino et al., 1989). The insulin receptor is synthesized as a 
single-chain precursor polypeptide containing 1343 (Sudhof et al., 1985) or 1355 (Williams et 
al., 1989) amino acids preceded by a 27-residue NH,-terminal signal sequence. During 
processing and transport to the cell surface, the 27-amino acid leader sequence is cleaved, and 
oligosaccharide side chains are added at specific glycosylation sites. Two monomers associate 
to form a dimeric structure, and a cleavage site consisting of four basic amino acids (Arg-Lys-
Arg-Arg; positions 720-723) is removed, resulting in discrete α and β subunits. These subunits 
are held together by αβ-disulfide bonds to form the mature heterotetrameric αβ-insulin 
receptor. The two identical α-subunits are entirely extracellular and contain either 719 or 731 
residues, depending on the presence or absence of a 12-amino acid insert (positions 720-731), 
which arises by alternate splicing of exon 11 into the insulin-receptor mRNA transcript in a 
tissue-specific manner (McClain et al., 1989; Seino and Bell, 1989). The β-subunit is a 620- 
residue membrane-spanning protein containing an extracellular region of 194 residues, a 
transmembrane anchoring domain of 23 amino acids, and a 403-residue cytoplasmic extension. 
Activation of the insulin receptor on the plasma membrane of cells by binding of insulin is the 
initial event that triggers the insulin receptor-signalling cascade, leading to the multiple cellular 
responses induced by insulin (Ullrich et al., 1985). Homozygous or compound-heterozygous 
mutations in the insulin receptor gene are found in patients with syndromes of severe insulin 
resistance (Williams et al., 1989). Moreover, in patients whose insulin receptor mutations do 
not lead to a complete loss of insulin receptor function, milder syndromes of insulin resistance 
are reported, such as the Rabson-Mendenhall syndrome (OMIM 262190) and type A insulin 
resistance (OMIM147670) (Williams et al., 1989; Yarden and Ullrich, 1989; Yarden and 
Ullrich, 1988). The less severe phenotype of these patients is believed to result from the 
retention of some functionality by these mutant insulin receptors. In 1988, the query of whether 
mutations in the insulin receptor (INSR) gene account for the insulin resistance in patients with 
non-insulin dependent diabetes mellitus (NIDDM) was raised (Kadowaki et al., 1988). 
 Subsequently reports of NIDDM cases carrying mutations at INSR were observed (Taira et al., 
1989). These mutations end in receptors with slightly decreased kinase activity or affinity for 
insulin. With such cases, environmental factors including obesity may trigger the onset of 
diabetes. A reduction in the number of insulin receptors in obese people is also now known to 
cause resistance to insulin (Taira et al., 1989). Proper diet and normal blood sugar levels may 
in turn improve the insulin excretion capacity by improving the function of the receptors (Taira 
et al., 1989). A study on tyrosine kinase domain of insulin receptor gene of 103 patients 
revealed Arg 1152 Gln mutation (Cocozza et al., 1992). Another study detected Gly 1008 Val 
in tyrosine kinase domain of insulin receptor gene which related to insulin resistance (Nozaki 
et al., 1993).  A Leu 1193 Trp mutation, causing defective tyrosine kinase activity was detected 
(Iwanishi et al., 1993). A report on leu 1153Met mutation in tyrosine kinase domain of insulin 
receptor gene was observed in another study (Cama et al.,1991) Presence of Thr 831 Aal and 
Try 1334 Cys mutations (Kan et al.,1995); and Met 958 Val mutation were also reported 
(Elbein et al.,1993). Imano and Kawamori detected homozygote mutations in tyrosine kinase 
domain of insulin receptor gene, and proposed the more severity of the disease compared to 
those harbouring heterozygote mutations in tyrosine kinase domain of insulin receptor gene 
(Imano and Kawamori, 1994). A missense Arg 981 Gln and nonsense mutations in tyrosine 
kinase domain of insulin receptor gene were reported (Kusari et al., 1991). Missense mutation 
(Arg 1174 Gln) was screened in tyrosine kinase domain of insulin receptor gene related to 
NIDDM (Hojlund et al., 2004). Review of the literature and sequences of exon 3 identified 
four possible regions subject to genetic variation with a potential of five polymorphisms: a 
nonsynonymous transition (T↔C) in codon 233 (Seino et al., 1990), a synonymous 
substitution at codon 234 (GAC to GAT) (Kadowaki et al., 1990), a synonymous change at 
codon 276 (CAG to CAA), and two possible repeats just 5 of exon 3 (Seino et al., 1990a). 
Each of the three substitutions predicts a restriction site difference: MspI, FokI, and RsaI 
(3313C allele, 3317T and 3443T), respectively. These polymorphisms are located within exon 
3, close to exon 2, which is the region that codes for the insulin binding site on the receptor 
(Hanis and Bertin, 1992). Another polymorphism, the NsiI RFLP at exon 8, has been 
associated with arterial hypertension (Schrader et al., 1996). Very few studies have been 
carried out on the polymorphic sites in exon 3 of INSR gene; however the documented results 
are conflicting (Kadowaki et al., 1990; Seino et al., 1990; Hanis and Bertin, 1992; Kazemi et 
al., 2009). Biochemical analyses of the various mutations/polymorphisms seen in patients with 
insulin-resistant syndromes provide insight into the residues of the insulin receptor that are 
critical for correct functioning and processing. Furthermore, by studying multiple patients with 
 the same mutation/polymorphism, insight can be obtained into the extent of genetic 
background an important modulator of phenotypic expression of insulin receptor gene. 
2.8.2. Leptin receptor (LEPR) gene 
The “obese” locus was first described 6 decades ago (Ingalls et al., 1950) and was later shown 
by positional cloning to be the LEP gene that encodes a secreted protein, leptin (Zhang et al., 
1994). Mice and humans homozygous for a leptin gene mutation (Lep ob/ob) develop 
hyperphagia, early-onset obesity, severe IR, steatosis, hypothalamic hypogonadism, deficits of 
the thyroid and growth hormone axes, and immunosuppression (Montague and Farooqi, 1997; 
Ahima et al., 2006). Circulating concentrations of leptin reflect fat cell stores – increasing with 
overfeeding and decreasing with starvation. Leptin administration to obese leptin-deficient 
animals has reversed their hyperphagia, hypothermia, decreased locomotor activity, and all 
neuroendocrine and immunological abnormalities (Friedman and Halaas, 1998). Leptin therapy 
also dramatically reduced body weight (mostly fat mass) in four children (Farooqi et al., 1999; 
2002; Gibson et al., 2004) and three adults (Licinio et al., 2004) with leptin deficiency. Leptin 
is expressed mainly in WAT adipocytes, though low levels are produced in the stomach, 
mammary gland, placenta, and skeletal muscle (Ahima et al., 2006). 
The diverse nature of leptin is supported by the universal distribution of leptin receptor 
(LEPR). LEPR was cloned in 1995 (Tartaglia et al., 1995). It was identified to be the same 
gene which was mutated in diabetic db/db mouse (Lee et al., 1996), which had earlier been 
shown to have a similar phenotype to ob/ob mouse, but to be resistant to leptin treatment 
(Leibel et al., 1997). Also the leptin resistant Zucker fatty rat (fa/fa) carries a mutation in the 
LEPR gene (Iida et al., 1996). LEPR localises to chromosome 1p31 (Chung et al., 1996a), and 
the long form has 18 exons (Chung et al., 1996b). LEPR is a single transmembrane-domain 
receptor, which displays a structural similarity to the class I cytokine receptor family 
(Fruhbeck, 2006). The LEPR is produced in several alternatively spliced forms, designated 
LEPRa–LEPRf, that share the common extracellular domain (>800 aa) and the transmembrane 
domain (34 aa), and have a variable intracellular domain, characteristic of each of the 52 
isoforms (Fruhbeck, 2006). “Short forms” of LEPR may have roles in binding (LEPRe), 
transport (LEPRa), and clearance (LEPRc and LEPRd) of leptin (Margetic et al., 2002), 
whereas only LEPRb, the “long form” (1162 aa), encodes all protein motifs capable of 
activating the janus kinase – signal transduction and transcription (JAK-STAT) pathway which 
in turn stimulates transcription of target genes (Gullicksen et al., 2003). Although regulation of 
 hypothalamic neuropeptide gene expression by leptin is well described, the role of JAK–STAT 
signalling in this response remains uncertain, as leptin can affect neuronal firing rate 
independently of its transcriptional effects. For example, a subset of ‘glucose-responsive’ 
neurons in the hypothalamus become hyperpolarized (and therefore decrease their firing rate) 
within minutes of leptin application (Spanswick et al., 1997). Glucose influences the 
membrane potential of glucose-responsive neurons indirectly through its oxidation to generate 
ATP, which in turn controls the activity of ATP-sensitive potassium channels (KATP) in the 
plasma membrane (Dunn-Meynell et al., 1998). Closure of KATP channels in response to 
increasing intracellular concentrations of ATP (relative to ADP) raises intracellular [K+], 
which depolarizes the cell and increases its firing rate. Because leptin maintains KATP channels 
in the open configuration (Spanswick et al., 1997), positively charged K+ ions diffuse out of 
the cell and lower its membrane potential. This effect on KATP channels can be detected even in 
isolated patches of plasma membrane, excluding a mechanism involving transcriptional effects 
of leptin. 
Leptin resistance is common in obesity, and the mechanisms responsible for this phenomenon 
may include defects of the leptin receptor, leptin transport, genes involved in leptin signal 
transduction, or defective transport of leptin across the blood-brain barrier (Gullicksen et al., 
2003). At the level of pancreatic β-cell, leptin resistance may contribute to dysregulation of the 
adipo-insular axis and promote the development of hyperinsulinaemia and manifest as T2DM 
in overweight patients (Seufert, 2004). Mutations in LEPR are rare; in a recent study, subjects 
with hyperphagia and severe early-onset obesity were sequenced for LEPR mutations, and only 
8 nonsense or missense mutations were found, each resulting in impaired receptor signalling 
(Farooqi et al., 2007). However, the LEPR gene is highly polymorphic, and associates with 
obesity traits in several studies. The long form of the LEPR gene is expressed in pancreatic 
beta-cell (Kieffer et al., 1996), where it is proposed to mediate leptin-induced inhibition of 
insulin secretion (Kieffer et al., 1997; Emilsson et al., 1997). This mechanism has been 
suggested to explain the occurrence of hyperinsulinaemia in ob/ob and db/db mice (Kieffer et 
al., 1997). Furthermore, linkage between the acute insulin response and the microsatellite 
marker D1S198 flanking the leptin receptor gene, has also been reported in Pima Indians 
(Thompson et al., 1995). Several studies thus favour the idea that the leptin receptor may play 
a role in regulation of insulin secretion. 
A number of sequence determinants are known to affect mammalian mRNA abundance (Ross, 
1995). Occurrence of multiple copies of the core sequence UUAUUUA(U/A)(U/A), designated 
as the A+U destabilizing element (AUDE), is known to destabilize a variety of mRNA species 
 (Brown et al., 1996). A closely reminiscent sequence of 5-UUACUUUAUA-3  is created in 
the 3 -UTR of the insertion allele; whether the extra C present in this sequence eliminates the 
destabilizing effect of the core sequence, is currently not known. A common CTTTA-
pentanucleotide Del/Ins variant of the 3’-UTR part of the LEPR gene is believed to generate an 
A+U-rich sequence, that should be able to form a stemloop structure, which may affect mRNA 
stability in the cell (Oksanen et al., 1998). The Del/Ins variant has been found to be associated 
with serum insulin levels (Oksanen et al., 1998;  Lakka et al., 2000), serum high density 
lipoprotein (HDL)-cholesterol and apolipoprotein A (apoA)-I levels (Nishikai et al., 2004), and 
susceptibility to T2DM (Lakka et al., 2000). It is, potentially, of greater importance that a 
motif compatible with stem-loop formation, with eight complementary nucleotides forming the 
stem and ten nucleotides the loop, is generated in the 3 -UTR of the pentanucleotide insertion-
containing mRNA molecule (Fig 1).  
Stem-loop sequences have been detected in a number of transcripts, including mRNAs for 
histones, transferrin receptor, insulin-like growth factor II and cytokines (Ross, 1995; Brown et 
al., 1996). Although the mechanisms by which stem-loops affect mRNA stability is not 
completely understood, in many cases these motifs have been shown to bind to regulatory 
proteins, which in turn could affect the rate of degradation and/or translation of mRNA (Ross, 
1995). Associations of LEPR Ins/Del variants with diabetes and related traits are listed in the 
Table 2. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1: Putative stem-loop structure generated by the presence 
of the CUUUA insertion (marked with asterisks) in the leptin 
receptor mRNA 
 
  
Table 2: Associations of LEPR Ins/Del variants with diabetes and related traits  
Subjects Variant Risk 
allele 
Association Reference 
Finnish 
Caucasoid 
 
3’UTR 
del/ins Del Higher serum insulin 
Oksanen et al., 1998 
Caucasoid 
(men) 
 
3’UTR 
del/ins Del 
Higher serum insulin 
Higher risk of diabetes 
Lakka et al., 2000 
Japanese 
 
3’UTR 
del/ins Ins 
Lower HDL-cholesterol 
and apoA-I Levels 
Nishikai et al., 2004 
Finnish 3’UTR del/ins Del Higher body weight 
Salopuro et al., 2005 
Multicentre 
study 
 
3’UTR 
del/ins Del 
Lower weight and WC 
reduction 
Zacharova et al., 2005 
Italian 3’UTR del/ins Del 
Higher risk of diabetes 
Higher serum Insulin 
levels 
Nannipieri et al., 2006 
HDL: high density lipoprotein, apoA: apolipoprotein A, WC: waist circumference 
Del: Deletion, Ins: Insertion 
 2.8.3 β3-adrenergic receptor (ADRB3) gene 
The β3-adrenergic receptor crosses the cell membrane seven times, is coupled to guanine-
nucleotide–binding (G) proteins, and is localized in adipose tissue (Figure 2.5). Stimulation of 
the receptor by β3-adrenergic agonists activates adenylate cyclase, which increases intracellular 
concentrations of cyclic AMP (cAMP) and results in increased lipolysis and thermogenesis 
(Emorine et al., 1989; Krief et al., 1993; Spronsen et al., 1993). There is evidence that 
molecular abnormalities in the β3-adrenergic receptor may lead to obesity and T2DM. 
Expression of the receptor is markedly decreased in rodent models of obesity (Muzzin et al., 
1991; Collins et al., 1994); mice with knockout (disruption) of the gene for the receptor have 
marked reductions in lipolysis stimulated by β3-agonists (Susulic et al., 1995) and β3-specific 
agonists have potent antiobesity and antidiabetic effects in both animals (Mitchell et al., 1992; 
Himms et al., 1994) and humans (Mitchell et al., 1989; 1992).  
The β3-adrenergic receptor is expressed in visceral fat in humans 11 and is considered 
responsible for increases in lipolysis and the delivery of free fatty acid into the portal vein 
(Lönnqvist et al., 1995). An increase in visceral fat mass, in turn, correlates with resistance to 
insulin in skeletal muscle (Colberg et al., 1995). Any abnormality in the β3-adrenergic receptor 
could therefore explain the link between abdominal obesity and insulin resistance.  
The β3-adrenergic receptor (ADRB3) is mainly expressed in adipose tissue, and contributes to 
variations in energy expenditure and body fat distribution (Clement et al., 1995; Shuldiner and 
Sabra, 2001; Lowell and Bachman, 2003). Polymorphisms of the ADRB3 have been suggested 
to participate in the etiopathogenesis of obesity (Arner, 1995; Shuldiner and Sabra, 2001). In 
particular, a single nucleotide polymorphism in the ADRB3 gene (substitution of tryptophan 64 
with arginine (Trp64Arg)) has been associated with obesity, insulin resistance, abnormal lipid 
profile and arterial hypertension (Walston et al., 1995; Widen et al., 1995; Urhammer et al., 
1996; Strazzullo et al., 2001; Hallman et al., 2004; Hao et al., 2004). However, since the 
prevalence of the Trp64Arg mutation differs among ethnic groups (Shuldiner and Sabra, 2001), 
other studies have failed to show any relationship between this polymorphism and obesity 
(Kurokawa et al., 2001; Frederiksen et al., 2003). Furthermore, it has been suggested that the 
association of this ADRB3 polymorphism with body weight and obesity related phenotypes 
may be dependent upon the presence of other susceptibility genes and/or exposure to other 
environmental factors (Shuldiner and Sabra, 2001). Several case-control studies revealed that 
the polymorphism of the β3-adrenergic receptor gene (Trp64Arg) is associated with the 
development of NIDDM, insulin resistance, obesity and syndrome X (Reaven, 1988). It was 
 also reported that the Trp64Arg polymorphism is significantly associated with the development 
of NIDDM and obesity in Pima Indians (Wallston et al., 1995), Finns (Widen et al., 1995) and 
French Caucasians (Clement et al., 1995). Moreover, the locus of Trp64Arg mutation was 
reported to be associated with the development of obesity and hyperinsulinemia in Japanese 
(Kadowaki et al., 1995; Yoshida et al., 1995; Fujisawa et al., 1996). However, other studies 
suggested that this polymorphism is not associated with the development of NIDDM and 
obesity (Li et al., 1996; Oksanen et al., 1996; Urhammer et al., 1996; Nagase et al., 1997; 
Ueda et al., 1997; Azuma et al., 1998). Various studies showing associations of Trp64Arg 
variant in ADRB3 gene with diabetes and related traits are listed in chronological order in 
Table 3. 
 
 Table 3: Associations of Trp64Arg variant in ADRB3 gene with diabetes and related traits 
T2DM, Type 2 diabetes mellitus; NGT, normal glucose tolerance; WHR, waist-to-hip ratio; 
OGTT, oral glucose tolerance test; dBP, diastolic blood pressure; BMI, body mass index; 
VAT, visceral adipose tissue; sBP, systolic blood pressure; TG, triglyceride; HDL, high 
density lipoprotein;  WC, waist circumference. 
 
 
 
 
Subjects Risk 
allele 
Association Reference 
Pima Indian Arg Lower age at onset of T2DM Walston et al., 
1995 
French Caucasoid Arg Higher weight gain during adult life Clement et al., 
1995 
Finnish Caucasoid 
 
Arg Lower age at onset of T2DM 
Higher WHR, insulin response in 
OGTT, dBP, and lower rate of glucose 
disposal (in NGT) 
Widen et al., 
1995 
Japanese 
 
Arg Higher BMI, fasting and 2h insulin in 
OGTT (in NGT) 
Kadowaki et al., 
1995 
Finnish Caucasoid 
 
Arg Earlier onset of obesity Oksanen et al., 
1996 
Japanese 
 
Arg Greater VAT area, higher body fat, sBP, 
glucose, insulin, cholesterol, and TG 
levels,Lower HDL-cholesterol 
Sakane et al., 
1997 
Mexican American 
 
Arg Lower age at onset of T2DM 
Higher 2h insulin in OGTT 
Silver et al., 
1997 
Mexican American Arg Higher BMI, fat mass, and WC Mitchell et al., 
1998 
Swedish 
Caucasoid 
 
Arg Higher BMI, lower sensitivity for 
receptor agonist in VAT adipocytes 
Hoffstedt et al., 
1999 
Mexican American 
 
Arg Interaction with PPARγ2 Pro12Ala on 
higher BMI, insulin, and leptin levels 
Hsueh et al., 
2001 
Chinese (neonates) Arg Higher insulin and insulin-to-glucose 
ratio 
Wang et al., 
2004 
Hungarian 
children 
 
Arg Higher weight, body fat, sBP, and 
insulin levels 
Erhardt et al., 
2005 
Japanese Trp Higher frequency of BP elevation Masuo et al., 
2005 
Turkish Trp Type 2 Diabetes Turgay, 2007 
Kyrgyz Arg Metabolic syndrome Mirrakhimov et 
al., 2011 
 AIM & OBJECTIVES 
The aim of the research is to determine for the first time the prevalence of various 
polymorphisms in Insulin receptor (INSR), leptin receptor (LEPR) and β3-adrenergic receptor 
(ADRB3) genes in the Type 2 Diabetes Mellitus patients of Kashmir valley and appraise their 
possible associations with the risk factors and severity of disease.  
• To verify a non-synonymous transition Leu233Pro (T↔C), and two 
synonymous substitutions Asp234 (C↔T) and Gln276 (G↔A) in the exon 3 
of INSR gene in patients with Type 2 Diabetes Mellitus. 
• To evaluate the prevalence of 3΄ UTR Ins/Del polymorphism of LEPR gene in 
Type 2 Diabetes Mellitus. 
• To assess the prevalence and association of Trp64Arg (T↔C) polymorphism 
in ADRB3 gene in Type 2 Diabetes Mellitus. 
• To correlate the genotypes with risk factors and severity of disease. 
 MATERIAL & METHODS 
The research entitled “Evaluation of Insulin receptor (INSR), Leptin receptor (LEPR) and β3-
adrenergic receptor (ADRB3) gene polymorphisms in Diabetes Mellitus patients of Kashmir 
valley” is a prospective research undertaken in the department of Biochemistry, University of 
Kashmir in collaboration with Sheri-I-Kashmir Institute of Medical Sciences (SKIMS), 
Srinagar Kashmir. 
4.1 Sample Size 
A total of 500 ethnic Kashmiri subjects were selected for the study, which includes 200 type 2 
Diabetes mellitus patients and 300 healthy controls. 
4.2 Definition of Case 
Selection of cases was based on American Diabetes Association (ADA) and/or World Health 
Organisation (WHO) criteria for type 2 Diabetes Mellitus. The controls comprise of age and 
gender matched healthy non-diabetic subjects.  
4.2.1 Inclusion Criteria 
• Subjects with symptoms of diabetes (thirst, increased urination, unexplained weight 
loss) plus a random plasma glucose concentration > 200 mg/dL (11.1 mmol/L) 
• Subjects with fasting plasma glucose > 125 mg/dL (7.0 mmol/L) after an overnight 
(at least 8-hr) fast 
• Subjects with two-hour plasma glucose > 200 mg/dL (11.1 mmol/L) during a 
standard 75 g oral glucose tolerance test 
• Subjects with HbA1c level >6.5 % 
• Documented cases of diabetes mellitus 
4.2.2 Exclusion Criteria 
• Unwilling patients 
• HIV positive patients 
• Drug induced diabetes patients 
• Stress induced diabetes patients 
• Gestational diabetes patients 
• Genetic syndromes associated with diabetes 
• Subjects not complying with the requisite patient proforma  
 4.3 Anthropometric and Systemic measurements 
Weight and height were measured using standard anthropometric techniques with subjects in 
light-weight clothing without shoes. Waist circumference was measured midway between the 
lower rib margin and the iliac crest at the end of gentle expiration using a metal 
anthropometric tape. Anthropometric measurements, including Body Mass Index (BMI) and 
Waist to Hip ratio (WHR) were calculated for each subject. BMI was expressed as kg/m2. 
BMI is used to reflect the total body fat, while WHR is an indirect measurement of body fat 
centralization. Hypertension was defined as a systolic pressure >140 mmHg or diastolic 
pressure >90 mmHg. 
4.4 Sample Collection 
Collection of samples was conducted in the Endocrinology Department of SKIMS, Srinagar 
Kashmir. After proper consent from each subject, 3-4 ml of blood was collected in EDTA 
vacutainer. Plasma was separated and immediately sent for biochemical analysis. The samples 
were stored at -20º C until processed. DNA was extracted from peripheral leukocytes 
according to Phenol-Chloroform method (Sambrook and Russel, 2001). 
 Note:  Chemicals used and preparation of reagents are illustrated in Apendix I and Apendix II 
respectively. 
4.5 DNA extraction from Blood 
1. To 3 ml of blood, 9 ml of erythrocyte lysing buffer was added. 
2. The contents were shaken gently, incubated for 30 min on ice, and centrifuged at 4000 rpm 
for 10 min. 
3. The supernatant (blood waste) was removed and the pellet was resuspended in 9 ml of 
erythrocyte lysis buffer and centrifuged for 10 min at 4000 rpm. 
4. The supernatant was discarded. 5 ml of SE-buffer, 20 µl proteinase K (10mg/ml) and 100 µl 
20% SDS were added to the pellet. The contents were shaken gently and incubated overnight 
at 37°C in a water bath. During this step the white blood cells' membranes are denatured and 
DNA goes out in solution. 
5. Next day, equal volume of Tris-equilibrated (TE) phenol was added to the contents and 
shaken slightly for 10 min. The tubes were centrifuged at 3000 rpm for 5 minutes. 
6. The supernatant was aspirated and transferred into a new tube. Equal volume of 
phenol/chloroform/isoamyl alcohol (25:24:1) was added to the contents. The emulsion was 
then centrifuged for 10 min at 2000 rpm with minimal breaking force. After centrifugation 
 two phases were observed: DNA is extracted into the supernatant and proteins separated into 
the lower phase. 
7. The aqueous phase was removed using a Pasteur pipette without disturbing the protein 
interface and was transferred into a new tube to which equal volume of 
chloroform/isoamylalcohol (24:1) were added. The tubes were shaken for 10 min and 
centrifuged at 3000 rpm for 5 min. 
8. The upper aqueous phase (containing the DNA) was transferred into a clean and sterile 
conical centrifuge tube using a sterile Pasteur pipette, followed by the addition of 300µl of 
chilled 3M sodium acetate (pH 5.2) and an equal volume of isopropanol along the sides of the 
tube. 
9. DNA was precipitated by gentle swirling of the tube and observed visually as a white thread 
like strand that was spooled out using a cut-tip and transferred into a 1.5 ml eppendorf tube. 
10. The DNA was washed twice in 70% ethanol by inversion to clean it from any 
remaining salts and the tube was centrifuged at 11000g for 4 min. The supernatant was 
discarded without disturbing the DNA pellet.  
11. After discarding the supernatant the pellet was air dried from excess ethanol by 
leaving the tubes open and inverted. 
12. The dried pellet was re-suspended in 300 µl of DNA storage buffer and left overnight 
at 37º C for complete dissolution. 
13. DNA purity and concentration was determined spectrophotometerically (Pharmacia, 
Gene Quant) by measuring the absorbance at 260 nm. Purity was assessed by the A260/280 
ratio. 
14. The quality of extracted DNA was determined by electrophoresis, on 1% agarose gel. 
15. DNA was dissolved in TE-storage buffer at -20ºC for longer storage and shelf life. 
4.6 Genotyping 
4.6.1 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR), a powerful technique developed by a team headed by Kary 
Mullis at Cetus Corporation, is used to amplify a segment of DNA in vitro (Saiki et al., 1985; 
Mullis et al., 1987). This method utilizes a DNA polymerase and two oligonucleotide primers 
to synthesize a specific DNA from a single stranded template sequence. The oligonucleotides 
typically have different sequences and are complementary to sequences that lie on opposite 
strands of the template DNA and flank the segment of DNA that is to be amplified. The length 
of the primers usually 20 bases or more must be sufficient to overcome the statistical likelihood 
 that their sequence would occur randomly in the overwhelmingly large number of non-target 
DNA sequences in the sample. PCR is carried out in a series of cycles. Each cycle begins with 
a denaturation step to render the target DNA single stranded. This is followed by an annealing 
step during which the primers anneal to their complementary sequences so that their 3' 
hydroxyl ends face the target. Finally each primer is extended through the target region by the 
action of DNA polymerase. Since the products of one round of amplification serve as templates 
for the next cycle, the three step cycles are repeated until a sufficient amount of the product is 
produced. The major product of this exponential reaction is a segment of double-stranded DNA 
whose termini are defined by the 5' termini of the oligonucleotide primers and whose length is 
defined by the distance between the primers. The earliest PCR experiments utilised the Klenow 
fragment of Escherichia coli DNA polymerase I at a temperature of 37°C and often produced 
incompletely pure target products as judged by gel electrophoresis. However, the isolation of a 
heat-resistant DNA polymerase from Thermus-aquaticus (Taq) (Chien et al., 1976) allows 
primer annealing and extension to be carried out at an elevated temperature, thereby reducing 
mismatched annealing to non-target sequences. This added selectivity results in the production 
of large amounts of virtually pure target DNA. Another important advantage of Taq 
polymerase is that it escapes inactivation at higher temperatures and need not be replaced after 
every denaturation step. This has allowed automation of PCR using machines that have 
controlled heating and cooling capability.  
4.6.1.1 Procedure for PCR amplification of INSR, LEPR and ADRB3 genes 
All precautions were taken to ensure contamination free amplification of DNA.  The primer 
sequence, annealing temperatures and amplicon size is given in Table 4. For INSR gene, a 533 
bp segment of exon 3 encompassing the 233, 234 and 276 SNPs was amplified using a 
common primer pair. A 114/119 bp sequence (depending upon the Del or Ins allele present) in 
3 UTR of LEPR gene was amplified. In ADRB3 gene, a 250 bp region was amplified 
encompassing the Trp64Arg polymorphism.  
Protocol 
The amplification reaction was carried out in 25µl reaction volume in 0.2ml PCR tubes. The 
reaction contained the following reagent volumes:- 
⇒ 10X PCR buffer    2.5µl 
⇒ 10mM dNTP mix    0.5µl 
⇒ Forward Primer    0.5µl 
⇒ Reverse Primer     0.5µl 
 ⇒ Taq DNA polymerase (1U)   0.2µl 
⇒ Genomic DNA (250 ng)   1.0µl 
⇒ Deionized water    19.8µl 
      Total volume    25.0µl 
For 50µl reaction (especially for sequencing) the reagent volumes along with template DNA 
were simply doubled.  The following temperature profile was used for amplification:-  
1. Initial denaturation     95°C for 4 min 
2. Denaturation    95°C for 30 sec 
3. Annealing    x°C for 30 sec* 
4. Extension    72°C for 30 sec 
5. Final Extension   72°C for 7 min.  
* x was 3-5°C lower than the melting temperature (Tm) of the primers. 
Temperature profile from step 2-4 was used for 35 cycles before final extension.  
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4.6.1.2 Detection of PCR products 
The amplified products were detected by electrophoresis on 2% agarose in a mini gel system. 
The fidelity of amplicons was confirmed by running a 100bp DNA marker along with the PCR 
products. Electrophoresis was carried out at 100 volts until the loading dye had migrated to a 
distance of two thirds from the wells. The gel was examined on a Gel-documentation system and 
photographed. 
4.6.2 Restriction Fragment Length Polymorphism (RFLP) 
Restriction fragment length polymorphism (RFLP) is a technique that exploits variations in 
homologous DNA sequences that result from differing locations of restriction enzyme sites. The 
basic technique for detecting RFLPs involves fragmenting a sample of DNA by a restriction 
enzyme, which can recognize and cut DNA wherever a specific short sequence occurs, in a 
process known as a restriction digestion. The resulting DNA fragments are then separated by 
length through agarose gel electrophoresis. 
The SNPs in INSR and ADRB3 genes were analyzed by RFLP. The enzyme characteristics, 
RFLP programme of INSR and ADRB3 genes are shown in Table 5a, 5b and 5c respectively. 
The PCR products of INSR gene were simultaneously digested with MspI, FokI and RsaI. Each 
enzyme is characteristic of the restriction site created by the 233, 234 and 276 SNPs respectively. 
The wild alleles remain uncut upon digestion with these restriction enzymes where as the variant 
allele is digested giving a fragment characteristic of the variant present at the polymorphic site. 
The Trp64Arg (T↔C) polymorphism in ADRB3 gene was assessed using MspI restriction 
enzyme. The wild allele (TT) remains uncut where as the variant allele (CC) is digested into 158 
bp and 97 bp fragments. The restriction digestion products were analysed on 2.5% agarose gel 
electrophoresis. 
 
 
 
  
Table 5a: Characteristics of restriction enzymes 
Enzyme Restriction site Source Conc. 
MspI 5...C↓CGG…3  
3 …GGC↑C…5  Moraxella species 
10U/µl 
RsaI 5 …GT↓AC…3  
3 …CA↑TG…5  Rhodobacter sphaeroides 
10U/µl 
FokI 5 …GGATG(N)9↓NNNN
…3  
3 …CCTAC(N)13↑…5  
Flavobacterium 
okeanokoites 
10U/µl 
 
Table 5b: RFLP programme for INSR gene 
Reagents Volume Incubation 
Nuclease free Water 15µl 
Incubation was carried at 37°C for 12 
hours  
10x Buffer  2µl 
PCR Product 10µl 
MspI 
RsaI 
FokI 
1µl 
1µl 
1µl 
 
Table 5c: RFLP programme for ADRB3 gene 
Reagents Volume Incubation 
Nuclease free Water 17µl 
Incubation was carried at 37°C for 12 
hours  
10x Buffer  2µl 
PCR Product 10µl 
MspI 1µl 
  
4.6.3 Single-strand conformation polymorphism (SSCP) 
Single-strand conformation polymorphism (SSCP) technique is a simple and efficient means 
to detect any small alteration in PCR-amplified product. It is based on the assumption that 
slight nucleotide change affects the migration of single-stranded DNA fragment and, 
therefore, results in visible mobility shifts across a non-denaturing polyacrylamide gel (Orita 
et al., 1989). Polyacrylamide gel is used for analysis of DNA with specialized buffer systems 
and without urea. In nondenaturing PAGE the components used to synthesize matrix are 
acrylamide monomers, N, N-methylene bisacrylamide (bis), ammonium persulphate (APS) 
and N,N,N,N -tetramethylenediamine (TEMED). APS when dissolved in water generates 
free radicals, which activate acrylamide monomers inducing them to react with other 
acrylamide molecules forming long chains.  
4.6.3.1 Procedure for SSCP to detect Del/Ins polymorphism in LEPR gene 
A 5 bp Del/Ins polymorphism in LEPR gene was screened using PCR-SSCP. The 114/199 bp 
region was amplified using PCR technique. Del/Ins polymorphism was assessed by SSCP. 
The SSCP technique involved the following steps: 
4.6.3.1.1. Preparation of glass plates 
A pair of glass plates one notched and the other unnotched (21.5x30.0) cm2 and spacers were 
thoroughly rinsed with deionised water. To assemble the plates, two spacers (0.4mm thick) 
were placed on the edges of the plate. The plates were clamped together on one side with bull 
dog binder clips, and the other side and the bottom were sealed with gel sealing tape.  
4.6.3.1.2. Preparation of gel solution 
12% non-denaturing polyacrylamide gel was used to analyse the PCR products. The gel was 
prepared as follows:- 
⇒ 30% acrylamide:bis-acrylamide stock solution  40 ml 
⇒ 5x TBE       20 ml 
⇒ 50% Glycerol       20 ml 
⇒ 10% Ammonium persulphate     0.7 ml 
⇒ Distilled water      19.3ml 
Total volume of the gel solution    100 ml  
50µl of TEMED was added to the gel solution just before pouring it into the mould of glass 
plates. 
4.6.3.1.3. Casting of the gel 
  
The glass plate mould was placed at a ~10° angle to the working table. 30ml of gel solution 
was drawn into a 50 ml hypodermic syringe ensuring no air bubble goes into the syringe. A 
thin stream of gel solution was allowed to flow at the top corner between the plates. 
Immediately a comb was inserted into the gel solution to form the sample wells. The gel was 
allowed to polymerize for about 45 min. After polymerization the comb was removed and the 
wells were washed with 1x TBE buffer to remove any un-polymerized gel solution. 
4.6.3.1.4. Denaturation of PCR products 
5µl of each PCR product of LEPR gene was mixed with 15µl of formamide gel-loading buffer 
(see appendix 1), heat denatured at 95°C in thermocycler for 5 min and immediately chilled 
on ice for 10-15 min.  
4.6.3.1.5. Electrophoresis 
The glass plate mould with polymerized gel was assembled into an electrophoresis 
apparatus. The lower buffer reservoir was fitted to the electrophoresis apparatus and filled 
with 0.5x TBE made from the same stock as gel solution. With the help of Hamilton syringe 
5-6µl of sample (denatured PCR products+ formamide gel-loading buffer) was loaded on the 
gel. The upper buffer reservoir was then placed properly on the plates and filled with 0.5x 
TBE buffer. The electrodes were fitted to a high voltage power supply. Electrophoresis was 
carried out at a constant voltage of 3-4 V/cm of gel for nearly 16-18 hours. After 
electrophoresis was completed, the plates were removed from the electrophoresis apparatus 
and separated. The plate with the gel stuck to it was placed in a gel staining tray for silver 
staining. 
4.6.3.1.6. Silver staining 
Silver staining was used to detect the DNA bands (mobility shift) in the SSCP gel. Silver 
staining was performed as follows: 
1. To the gel in staining tray, gel fixing solution was added with volume sufficient to cover 
the gel by ~2-3mm. The gel was allowed to fix for 30 minutes. 
2. Gel fixing solution was removed by suction and the gel was rinsed twice with distilled 
water.  
3. Silver staining solution was added to stain the gel for 15-20 minutes. 
4. The silver staining solution was removed by suction and the gel was rinsed three times 
with distilled water. 
5. Developer was added and the gel was kept in the developer until brown to deep brown 
DNA bands appeared. Upon the appearance of bands, the developer was immediately 
removed and distilled water was added to wash the gel for 2 minutes. 
  
6. Distilled water was removed by suction and the developing was stopped by adding 
stopping solution for 10 minutes. 
7. After giving the stop solution treatment, the gel was immediately photographed and 
labelled for documentation. 
4.7 DNA sequencing 
10% of the PCR products of INSR and ADRB3 gene, and bands showing mobility shift in the 
LEPR gene were sent for sequencing. The services of Macrogen (South Korea) were availed 
for sequences. Results were obtained in the portable document format.  
4.8 Statistical analysis 
Statistical Package for Social Sciences (SPSS, version 16.0) and Java Stat software was used 
for statistical analysis. Data was described as Mean ± SD and percentage, unless stated 
otherwise. Inter group variants of metric data was measured by Students t-test at 95% 
confidence interval. The non metric data was analyzed by Mann Whitney-U test. Fischer’s 
exact test and odds ratio analysis was used for genotyping analysis where P value of <0.05 
was considered to be significant. Hardy and Weinberg equilibrium was determined by χ2 
analysis. 
  
RESULTS & DISCUSSION 
5.1 Anthropometric, Systemic and Clinical Parameters of study and control population 
This study comprised of 500 subjects ethnic Kashmiri subjects. 200 cases of T2DM and 300 
non-diabetic controls were evaluated. The comparison of anthropometric, systemic and 
clinical parameters between study and control population is shown in Table 6. The mean age 
of cases and controls was 50.4 ± 11.1years and 49.2 ± 12.4 years respectively. Subjects were 
matched for age and gender. In both cases and controls, the predominant age group was 51-60 
years (Fig 2). Mean BMI of cases and controls was 24.2±5.3 kg/m2 and 21.2±3.3 kg/m2, 
respectively (Fig 3). The cases presented with higher BMI and WHR as compared to controls 
(p<0.001). This is indicative of the role of central obesity in the etiology of T2DM. The 
systemic examination showed that 54% of cases were hypertensive which was significantly 
higher than the control population (p<0.001). Overall, 85.5% of cases had abnormal levels of 
fasting blood sugar (>125 mg/dl) and 75.5% had abnormal post prandial glucose levels (>200 
mg/dl). The status of disease was determined by HbA1c levels (Fig 4). Only 22% of cases 
were in the controlled state (<7%), 29.5% of cases had mild status of diabetes (7-8%) whereas 
48.5% of cases suffered from uncontrolled diabetes (>8%). Deranged lipid profile was 
observed in study population (Fig 5). TG levels (>150 mg/dl) was observed in 55.5% of cases 
and 35% of control subjects (p<0.001). High LDL levels (>130) were seen in 18% of cases 
and only 8.7% of controls (p=0.002) where as 72.9% of cases had significantly lower HDL 
levels than in controls (p=0.003). Higher cholesterol levels (>200 mg/dl) was observed in 
cases than in controls (p<0.001). Elevated serum Creatinine levels (>1.5 mg/dl) were 
observed in 20.5% of cases as compared to 1.3% of controls (p<0.001).  Based on the type of 
treatment regimes, patients were categorized into three groups, viz. Insulin, oral antidiabetic 
drugs (OADs) and a combination of both. Out of these three groups, 40.5 % of the cases were 
on OADs, 31.5% were using insulin and 28% were undergoing both the treatments (Insulin + 
OADs). OADs was the most common form of treatment since majority of the patients 
recruited for the study were newly detected cases of type 2 diabetes mellitus. 
  
Table 6: Anthropometric, Systemic and Clinical parameters in Study and 
Control subjects 
BMI: Body Mass Index, WHR: Waist to Hip ratio, BP: Blood Pressure, BG-F: Blood Glucose Fasting, 
BG-PP: Blood Glucose Post Prandial, TGs: Triglycerides, LDL: Low Density Lipoproteins, HDL: 
High Density Lipoproteins, Chol: Cholesterol, Sr Cr: Serum creatinine. 
(Data expressed as Mean ± SD, Non metric data was analyzed by Mann Whitney-U test, P 
value for inter group variants measured by Student’s t-test at 95% confidence interval). 
 
Parameter Cases Controls P value 
Age (years) 50.4 ± 11.1 49.2 ± 12.4  0.9  
BMI (kg/m2) 24.2 ± 5.3  21.2 ± 3.3  < 0.001 
WHR 0.9 ± 0.1  0.8 ± 0.1  < 0.001 
BP (Systolic) 130.5 ± 20.7  124.0 ± 14.6  < 0.001 
BP (Diastolic) 81.8 ± 10.5 79.8 ± 8.9  0.040 
BG-F (mg/dl) 201.1 ± 86.8  78.9 ± 8.1  < 0.001 
BG-PP (mg/dl) 286.2 ± 116.9  100.3 ± 12.4  < 0.001 
HbA1c (%) 8.8 ± 2.5 5.0 ± 0.7 < 0.001 
TGs (mg/dl) 205.1 ± 123.2 152.5 ± 82.6  < 0.001 
LDL (mg/dl) 103.6 ± 27.6  88.1 ± 25.7 0.002 
HDL (mg/dl) 38.5 ± 9.2  41.9 ± 7.7  0.003 
Cholesterol (mg/dl) 159.7 ± 57.3  133.7 ± 46.3  < 0.001 
Sr Cr (mg/dl) 1.1 ± 0.5 0.7 ± 0.2  < 0.001 
  
Figure 2:  Age distribution of the study and control Subjects in years 
 
 
Figur
(Data expressed as %age) (Data expressed as %age)  
e 3: Body Mass Index (kg/m2) of study and control subjects
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    (Data expressed as %age) Figure 5: Lipid Profile of the study and control subjects 
  
5.2 Qualitative and Quantitative analysis of genomic DNA 
The purity of extracted genomic DNA was assessed using relative absorbance values 
(A260/280), the ratio ranged from 1.8-2. Concentration of extracted DNA was determined using 
the formula: 
Concentration = A260 x Absorbance factor (50µg/ml) x Dilution Factor. 
Integrity of genomic DNA was checked using 1% agarose gel electrophoresis. DNA was 
intact as shown by the presence of bands in the wells of the gel. 
5.3 Genotyping Analysis of INSR gene polymorphism  
In INSR gene, three SNPs located in the exon 3 were evaluated: a T↔C at codon 233, a 
C↔T at codon 234 and G↔A transition at codon 276. Only homozygous wild alleles were 
present and the frequency of T (233), C (234) and G (276) allele was same in both cases and 
controls. The 533 bp amplicon of INSR gene generated using polymerase chain reaction was 
digested individually as well as simultaneously with MspI, RsaI and FokI restriction enzymes. 
The digestion products were resolved on 2% agarose gel. No variation was observed in the 
exon 3 of INSR gene as the amplicons remained uncut after restriction digestion (Fig 6). The 
fidelity of restriction enzymes was cross checked in order to rule out the possibility of 
enzymatic inactivity. The results thus obtained were further validated by the sequencing 
report of samples that showed no variation (Fig 7a and 7b). The INSR gene was 
monomorphic for all three suspected polymorphisms in our population as no variation was 
observed in either cases or controls. 
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igure 6: PCR-RFLP gel picture of INSR gene 
ane 1: 100 bp DNA marker 
ane 2 and 6: Undigested samples (533 bp Amplicons) 
ane 3, 4 and 5: Amplicons digested with restriction enzymes MspI, RsaI 
and  FokI respectively 
ane 7 and 8: Amplicons digested simultaneously with restriction 
enzymes MspI, RsaI and FokI 
533 bp 
  
 
       
Figure 7a: Partial sequence electropherogram of INSR gene encompassing 
codon 233 and 234  
 
 
Figure 7b: Partial sequence electropherogram of INSR gene encompassing 
codon 276 
(*Homozygous wild alleles) 
  
5.4 Genotyping Analysis of LEPR gene polymorphism  
The 3 UTR Del/Ins polymorphism was assessed using PCR-SSCP technique. A 114/119 bp 
del/ins amplicon was generated using PCR (Fig 8a). The PCR products were subjected to 
SSCP on 12% non-denaturing polyacrylamide gel. Amplicons subjected to PAGE in double 
stranded state did not differ in their relative mobility thereby resolved as single conspicuous 
bands (Fig 8b). The amplicons maintained in single stranded state gave unique band patterns 
corresponding to each particular genotype. The relative mobility shift relies on intra-strand 
looping. Three genotypes were observed D/D, D/I and I/I: each with its unique band pattern 
(Fig 8c). The homozygous D/D genotype was present in 79.5% of cases and 24.7% of controls. 
20.5% of cases and 69.3% of controls exhibited the D/I genotype (Fig 9). The rare I/I genotype 
was present in only 6% of controls and absent in cases. The D/D genotype was significantly 
higher in the cases than in controls (p<0.001). The frequency of Del allele was 89.7% and 
59.3%, while as the frequency of Ins allele was 10.3% and 40.7% in cases and controls 
respectively (Table 7). The frequency of Del allele corresponds directly to the severity of 
disease as shown by the intra-group genotype analysis. The Del allele showed high significance 
with the severity of disease (Table 8). Among the cases, except for age and HDL levels, there 
was a significant association between the presence of Del allele and the severity of disease as 
indicated by intra group genotype analysis. The association also showed gender specificity with 
more number of females having the Del allele than the males (p<0.05). Del allele seems to be 
directly associated with higher BMI, WHR, HbA1c levels and various other risk factors of 
T2DM as well as metabolic syndrome. Frequency of Ins allele was predominant in control 
population than in cases suggesting a protective role imparted by Ins genotype against the 
prevalence and severity of T2DM in our population. The results were validated by the 
sequencing analysis of the 3  UTR of LEPR gene (Fig 10a, 10b and 1c). Sequencing report 
was in conformity with the genotyping results. 
  
 
Figure 8a: Amplified product of LEPR gene (114/119bp) 
 
Figure 8b: Gel picture of amplicons in double stranded state 
                1          2           3           4           5           6           7          8          9  
Figure 8c:  PCR-SSCP picture of amplicons in single stranded state 
Lane 1, 2, 6 and 7: Ins/Ins genotype (119 bp) 
Lane 3, 5, 8 and 9: Del/Del genotype (114 bp) 
Lane 4: Del/Ins genotype (114/119 bp) 
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igure 9: Histogram showing the distribution of LEPR (Del/Ins) alleles in study 
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homozygous, DI: Del/Ins heterozygous, II: Ins homozygous)
  
Table 7: Genotype analysis and Allele frequency of 3 UTR Del/Ins polymorphism in 
LEPR gene 
3  UTR Del/Ins 
Polymorphism 
Cases 
(%) 
Controls 
(%) 
OR 
(95 % CI) 
P value χ2 
Genotype 
DD 79.5 24.7    
DI 20.5 69.3 
10.90 
(7.07 -16.80) 
<0.001 60.4 
II 0.0 6.0 
77.35 
(7.75 - 63.72) 
<0.001 33.51 
DI+II 20.5 75.3 
11.84 
(7.70 - 18.23) 
<0.001 6.5 
DD 
(Risk Allele) 
Present 
 
79.5 
 
20.5 
24.7 
 
74.3 
 
11.84 
(7.70 - 18.23) 
 
<0.001 
 
Absent 
Allele 
Frequency 
Del 
 
89.7 
 
10.3 
59.3 
 
40.7 
 
6.00 
(3.61 - 9.97) 
 
<0.001     Ins 
 
Fischer’s exact test and odds ratio analysis was used for genotyping analysis where P 
value of <0.05 at 95% confidence interval was considered to be significant. 
DD (Deletion homozygous): Reference allele
  
Table 8: Genotypic correlation of 3 UTR Del/Ins polymorphism of LEPR gene 
with various clinical and laboratory features among the study population 
Parameter DD DI P value 
Age (years) 50.7 ±10.7 49.0 ±12.6 0.392 
BMI (kg/m2) 25.0 ±5.4 21.1 ±3.8 <0.001 
WHR 0.92 ±0.10 0.85 ±0.09 <0.001 
BP (Systolic) 132.5 ±20.7 122.7 ±19.0 0.006 
BP (Diastolic) 83.0 ±10.4 77.1 ±9.6 0.001 
BG-F (mg/dl) 212.7 ±91.4 156.1 ±43.9 <0.001 
BG-PP (mg/dl) 303.1 ±121.7 220.6 ±62.0 <0.001 
HbA1c (%) 9.4 ±2.5 6.6 ±0.6 <0.001 
TGs (mg/dl) 225.7 ±128.6 125.0 ±43.9 <0.001 
LDL (mg/dl) 108.8 ±27.1 83.3 ±18.9 <0.001 
HDL (mg/dl) 38.3 ±9.7 39.3 ±7.5 0.515 
Chol (mg/dl) 170.1 ±57.7 119.2 ±32.6 <0.001 
Sr Cr (mg/dl) 1.2 ±0.5 0.7 ±0.2 <0.001 
BMI: Body Mass Index, WHR: Waist to Hip ratio, BP: Blood Pressure, BG-F: Blood 
Glucose Fasting, BG-PP: Blood Glucose Post Prandial, TGs: Triglycerides, LDL: Low 
Density Lipoproteins, HDL: High Density Lipoproteins, Chol: Cholesterol, Sr Cr: Serum 
creatinine. 
(Data expressed as Mean ± SD, Non metric data was analyzed by Mann Whitney-U test, P 
value for inter group variants measured by Student’s t-test at 95% confidence interval). 
  
 
 
 
 
Figure 10a: Partial sequence electropherogram of 3 UTR Del/Ins 
polymorphism of LEPR gene (Homozygous wild Del/Del) 
Figure 10b. Partial sequence electropherogram of 3  UTR Del/Ins 
polymorphism of LEPR gene (Homozygous variant Ins/Ins) 
 
Figure 10c. Partial sequence electropherogram of 3  UTR Del/Ins 
polymorphism of LEPR gene (Heterozygous Del/Ins) 
 
 
  
5.5 Genotyping Analysis of ADRB3 gene polymorphism  
In ADRB3 gene, Trp64Arg (T↔C) polymorphism was evaluated in T2DM patients and non-
diabetic controls. A 255 bp amplicon was generated using polymerase chain reaction. 
Genotyping was done using RFLP method. The amplicons were digested using MspI 
restriction enzyme that differentiates the three genotypes: a 255 bp uncut TT (Trp64Trp) wild 
homozygous, a 158 + 97 bp variant homozygous (CC) and a 255 + 158 + 97 bp heterozygous 
(CT) genotype (Fig 11). Homozygous wild allele (TT) was present in 80.3% of controls and 
24.5% of cases. Control population exhibited high frequency of TT genotype as compared to 
cases in which the predominant genotype was CT allele (Fig 12). 71% of cases and 19% of 
controls carried the heterozygous CT genotype respectively. The CC homozygous variant 
genotype was present in 9% of cases and 0.7% of controls respectively. The frequency of C 
allele was observed to be 40% and 10.2% in cases and controls respectively (Table 9). This 
frequency distribution elucidates a correlation between the presence of C allele and the risk of 
T2DM, where as the T allele exerts a protective effect against T2DM in our population 
(p<0.05). On intra-group analysis of ADRB3 genotypes with clinical parameters and diabetic 
risk factors, a significant association was observed (p<0.05) that was suggestive of the 
deranged status and severity of T2DM with respect to the presence of C allele (Table 10). 
However the age of the subjects and HDL levels did not vary statistically across the 
genotypes. The highest association was observed in anthropometric measurements and serum 
creatinine levels. T allele frequency was observed to be 89.8% and 60% in controls and cases 
respectively which elucidates a protective effect conferred by the wild T allele and 
predisposition to disease and high risk factors by the variant C allele. Partial sequence 
electropherogram of homozygous wild allele and homozygous variant allele is shown in 
Figure 13a and Figure 13b respectively. 
  
 
 
 
 
 
 
Figure 11: PCR-RFLP picture of Trp64Arg (T↔C) polymorphism 
Lane 1and 2: Homozygous wild genotype (TT) 
Lane 3and 4: Heterozygous genotype (CT) 
Lane 5 and 6: Homozygous variant genotype (CC) 
Lane 7: Undigested amplicon 
Lane M: 100 bp DNA marker  
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igure 12: Histogram showing the distribution of ADRB3 Trp64Arg (T↔C) 
lleles in study and control population 
TT: Wild homozygous, CT: Heterozygous, CC: Variant homozygous)
  
Table 9: Genotype analysis and Allele frequency of Trp64Arg (T↔C) 
polymorphism in ADRB3 gene 
Trp64Arg (T↔C) 
Polymorphism 
Cases 
n 
(%) 
Controls 
n 
(%) 
OR 
(95% CI) 
P value χ2 
Genotypes 
TT 49 (24.5) 
241 
(80.3)  
 
CC 
9 
(4.5) 
2 
(0.7) 
0.04 
(0.01-0.19) 
<0.001 28.71 
CT 
142 
(71.0) 
57 
(19.0) 
0.08 
(0.05-0.12) 
<0.001 147 
CC+CT 
151 
(75.5) 
59 
(19.7) 
0.08 
(0.05-0.12) 
<0.001 153.5 
CC 
(Risk Allele) 
Present 4.5 0.7 
7.02 
(1.69-9.09) 
<0.05 
 
Absent 95.5 99.3 
Allele 
Frequency 
C 40 10.2 
5.89 
(3.69-9.39) 
<0.001 
T 60 89.8 
Fischer’s exact test and odds ratio analysis was used for genotyping analysis where 
P value of <0.05 at 95% confidence interval was considered to be significant. 
TT (Wild homozygous): Reference allele 
  
Table 10: Genotypic correlation of Trp64Arg (T↔C) polymorphism of   
ADRB3 gene with various clinical and laboratory features among the study 
population 
Parameter 
TT 
(n=49) 
CT 
(n=142) 
CC 
(n=9) 
P value 
Age (years) 50.3 ±12.2 50.5 ±10.9 49.6 ±9.3 0.969 
BMI (kg/m2) 20.9 ±3.7 24.9 ±5.3 30.5 ±3.3 <0.001 
WHR 0.85 ±0.09 0.91 ±0.09 1.01 ±0.06 <0.001 
BP (Systolic) 166.2 ±60.0 213.4 ±93.5 196.4 ±42.5 0.004 
BP (Diastolic) 238.6 ±95.9 303.4 ±121.9 273.2 ±56.9 0.003 
BG-F (mg/dl) 166.2 ±60.0 213.4 ±93.5 196.4 ±42.5 0.004 
BG-PP (mg/dl) 238.6 ±95.9 303.4 ±121.9 273.2 ±56.9 0.003 
HbA1c (%) 6.8 ±1.0 9.4 ±2.5 11.0 ±1.3 <0.001 
TGs (mg/dl) 129.6 ±51.9 226.5 ±131.0 277.9 ±99.6 <0.001 
LDL (mg/dl) 84.6 ±19.6 108.4 ±26.7 130.1 ±25.3 <0.001 
HDL (mg/dl) 40.2 ±7.5 38.3 ±9.8 33.0 ±6.6 0.086 
Chol (mg/dl) 121.2 ±32.0 168.6 ±57.1 228.1 ±47.6 <0.001 
Sr Cr (mg/dl) 0.8 ±0.3 1.2 ±0.5 1.4 ±0.3 <0.001 
BMI: Body Mass Index, WHR: Waist to Hip ratio, BP: Blood Pressure, BG-F: Blood 
Glucose Fasting, BG-PP: Blood Glucose Post Prandial, TGs: Triglycerides, LDL: Low 
Density Lipoproteins, HDL: High Density Lipoproteins, Chol: Cholesterol, Sr Cr: Serum 
creatinine. 
(Data expressed as Mean ± SD, Non metric data was analyzed by Mann Whitney-U test, P 
value for inter group variants measured by Student’s t-test at 95% confidence interval). 
  
 
Figure 13a: Partial sequence electropherogram of Trp64Arg (T↔C) 
polymorphism (wild homozygous) 
 
 
Figure 13b: Partial sequence electropherogram of Trp64Arg (T↔C) 
polymorphism (variant homozygous) 
 
 
 
 
 
 
  
DISCUSSION 
T2DM is an emerging epidemic in countries worldwide. Owing to the heterogeneity of this 
disorder, the risk factors and sequence of events remain to be elusive. Various factors are 
involved in its pathogenesis, progression and status. Both genetic and environmental factors 
are involved in its etiology. Ethnic variability can be partially attributed to non-genetic 
environmental and cultural factors. However, some studies show that diabetes prevalence 
differs markedly across ethnic groups, even when environmental exposures are similar. 
According to the WHO, between 2000 and 2030 most new cases of T2DM will emerge from 
India, China, and the USA, partly because these countries have some of the world’s largest 
populations, but also because these are ethnically at risk populations that are rapidly adopting 
obesogenic lifestyles. As originally hypothesized (Neel, 1962) natural selection may have 
favoured a metabolically efficient phenotype, based on a ‘thrifty genotype’ that increased the 
chances of surviving periods when food was scarce. The resulting thrifty phenotype could be 
characterized by a lower rate of energy expenditure and/or hyperphagia. Either or both of 
these characteristics would result in positive energy balance and increase fat stores during 
‘times of plenty’ which would be advantageous for survival during periods of drought and 
limited food supplies. However, in westernized societies, where food is plentiful, and 
typically high fat, this ‘thrifty genotype’ would be dis-advantageous, resulting in marked 
obesity and increased risk of T2DM. The “common-disease-common-variant” hypothesis 
states that the genetic predisposition is a result of multiple, relatively common genetic 
variants with small or modest effects. It has been estimated that ~20 genes are needed to 
explain 50% of the burden of a disease in the population if the predisposing genotypes are 
common (≥25%), even though the individual risk ratios are relatively small (RR=1.2-1.5) 
(Yang et al., 2005). Identification of the genetic elements of obesity and T2DM is one of the 
most important areas of research because discovery of the risk genes would certainly facilitate 
understanding of the disease, its complications and its treatment, cure, and prevention. 
 This study was sought in view of the alarming rise in T2DM rates in Kashmir valley. The 
aim of this study was to evaluate for the first time various polymorphisms in INSR, LEPR 
and ADRB3 genes. Correlation between various genotypes and clinical parameters was also 
determined in order to assess the role of genetic factors in the disease presentation and 
progression. A total of 200 cases of T2DM and 300 controls were analysed. The subjects 
were matched for age and gender. Highest prevalence of diabetes was observed in the age 
group of 51-60 years. Higher BMI and WHR were seen in cases as compared to controls. Our 
  
results are in accordance with the data showing that people with T2DM are overweight or 
obese primarily with central obesity (Astrup, 2001). This type of obesity is strongly 
associated with insulin resistance. In our study, the patients presented with dyslipidemia and 
characteristic pattern of lipid abnormalities commonly referred to as “diabetic dyslipidaemia”. 
Epidemiologic data suggest that for every unit of increase (i.e., between 2.7 and 3.6 kg) in 
BMI, risk of developing diabetes increases by 12% (Ford et al., 1997). Obesity is associated 
with at least 45 co-morbidities (Jung, 1997) including T2DM (Prentice, 1997). Many 
epidemiological studies have documented the strong association between obesity and T2DM. 
For example, the 14-year follow-up Nurses’ Health Study of 114,281 women aged 30–55 
years at baseline observed that BMI was the most important risk factor for T2DM (Colditz et 
al., 1995). Although many studies focus on body mass per se, body fat distribution is also an 
important independent risk factor for diabetes. A cross-sectional study of 5,080 individuals 
from different ethnic populations (Hindu and Muslim Asian Indians, African-origin Creoles, 
and Chinese Mauritians) showed that waist-to-hip ratio (WHR) is positively associated with 
T2DM independently of BMI (Dowse et al., 1991). A 13.5-year follow-up of 792 Swedish 
men aged 54 years confirmed the previous findings, suggesting that WHR is significantly 
associated with T2DM risk even after adjustment for BMI (Ohlson et al., 1985). 
Elevated levels of TGs, Cholesterol and LDL-C, and depressed HDL levels in cases differ 
significantly from non-diabetic controls. Diabetic dyslipidaemia results from lipoprotein 
dysmetabolism combined with abnormalities in insulin action. Hyperinsulinaemia is also 
associated with low HDL-C levels. In a 20- year follow-up of the Framingham Heart Study, 
hypertriglyceridemia and low HDL-C were associated with increased T2DM risk in both men 
and women (Kannel, 1985). We observed similar associations in our study, however 
dyslipidemia was observed in greater proportion of our control population, especially the 
depressed HDL levels and elevated TG levels. High blood pressure is not generally 
considered a causal factor in the development of T2DM. However, arterial endothelial 
dysfunction has been proposed as a causal link between elevated blood pressure and insulin 
resistance, which clearly could forge a causal link between blood pressure and diabetes 
(Meigs et al., 2004; 2006). T2DM and hypertension are strongly correlated, largely owing to 
their shared relationships with obesity and other lifestyle factors. Thus, the relationship 
between high blood pressure and T2DM may not be completely causal. Our study indicates a 
54% prevalence rate of hypertension in diabetic patients, which is higher than other 
documented reports (Arauz et al., 2003; Hu et al., 2005). However, a greater percentage of 
  
the controls in our study were also hypertensive. These facts are elusive of the presence of 
predisposing factors related to metabolic syndrome in our population. Dyslipidaemia and 
hypertension are independent risk factors for cardiovascular diseases. These observations 
specify that our population is prone to cardiovascular and atherosclerotic diseases. The 
changing dietary habits and sedentary lifestyle in our population due to western acculturation 
leads to the accumulation of predisposing risk factors that in association with genetic 
components precipitates the diabetic phenotype.  
HbA1c levels >8% were observed in nearly half (48.5%) of the cases which is suggestive of 
the extent of uncontrolled diabetes in our population. This discrepancy may be due to several 
reasons including unawareness, late detection and unresponsiveness and non-compliance to 
treatment.  A study demonstrated that the ratio of diagnosed to undiagnosed diabetes in our 
population is 1:10 (Zargar et al., 2008). The study reflects the meagre familiarity with 
diabetes care and management in patients from Kashmir valley. 
Serum creatinine is used to estimate glomerular filtration rate and to stage the level of chronic 
renal disease. Serum creatinine levels were elevated in 20.5% of the cases, suggesting 
impaired renal function secondary to the microvascular changes due to diabetes.  
We analysed three genes for polymorphic alleles and their association with T2DM. 
Genotyping analysis and sequencing reports were used to analyze these variants. In INSR 
gene, three polymorphisms (T↔C at codon 233, C↔T at codon 234 and G↔A transition at 
codon 276) located in exon 3 were evaluated. The results indicate that our population is 
monomorphic for these three polymorphisms as no variant allele was observed in either case 
or control. Similar results were observed in Mexican-American population (Craig and Hanis, 
1991). French and mixed ethnicity samples were also screened in another study that 
demonstrated monomorphic results for these three SNPs (Hanis and Bertin, 1992). Based on 
these replicative results by various studies, the previously documented study has been 
attributed to sequencing errors and cloning artifacts (Taylor et al., 1990). In a study on ethnic 
Iranian population, all 22 exons of the INSR gene were screened for variation. Several 
changes were reported including some novel polymorphisms (Kazemi et al., 2009). However, 
there was no report of the polymorphisms at codon 233, 234 and 276 (Kazemi et al., 2009). 
Thus, our observations on INSR gene polymorphism are in conformity with the studies 
conducted on several other populations (Hanis and Bertin, 1992; Kazemi et al., 2009). 
  
The insertion allele of the 3-UTR Del/Ins polymorphism has been associated with lower 
serum insulin levels in obese individuals (Oksanen et al., 1998). This finding has been 
confirmed in subsequent studies (Francke et al., 1997; Lakka et al., 2000). The 3 -UTR 
Del/Ins polymorphism of the LEPR gene generates an AU-rich sequence that should be able 
to form a stem-loop structure, which may affect mRNA stability in the cell (Oksanen et al., 
1998). We screened this pentanucleotide (CTTTA) Del/Ins in 3  UTR of LEPR gene. In our 
population the genotypes of this polymorphism were not in Hardy Weinberg equilibrium 
(χ2=57.22). This can be due to genetic mutation (drift) or natural selection for the locus in 
consideration. The Del/Ins genotype was predominantly found in control population. 
Frequency of Del allele was 89.7% and 59.3% and frequency of Ins allele was 10.3% and 
40.7% in cases and controls respectively. Del allele showed a linear association with the 
prevalence of diabetes as well as with the associated risk factors. According to our 
observations, Ins allele conferred a protective effect. The genotype and allele frequency of 
this polymorphism in our population is comparable to another study (Lakka et al., 2000) in 
which the carriers of the insertion allele had a 79% reduced risk of T2DM compared with 
non-carriers in the 4-year follow-up (Lakka et al., 2000). Previously a genetic linkage 
between the acute insulin response (AIR) and the microsatellite marker D1S198 was reported 
(Thompson et al., 1996). Due to the close physical distance between the leptin receptor locus 
and a putative genetic element controlling the AIR, the leptin receptor is also a candidate for 
the AIR genetic element. The earliest observable diabetic phenotype in the db/db mouse is 
hyperinsulinemia followed by obesity and β-cell failure (Hummel et al., 1996). Another study 
reported that the leptin receptor is expressed on β-cells, indicating that leptin may directly 
affect insulin secretion (Kieffer et al., 1996). 
Functional alterations in ADRB3 may promote the development of obesity and insulin 
resistance (Li et al., 1996; Clement et al., 1997). A change in the ADRB3 gene causes the 
substitution of the coding sequences from tryptophan into arginine in 64th position, and this is 
able to influence receptor’s affinity to nor-epinephrine and its interaction with Gs proteins in 
adipocytes (Walston et al., 1995). We analyzed the Trp64Arg polymorphism (T↔C) and 
ADRB3 genotypes were found to be in Hardy-Weinberg equilibrium in our population 
(χ2=0.48). Homozygous wild allele (TT) was present in 80.3% of controls and 24.5% of 
cases. 71% of cases and 19% of controls carried the heterozygous CT genotype respectively. 
The CC homozygous variant genotype was present in 9% of cases and 0.7% of controls 
respectively. Frequency of C allele was 40% and 10.2% in cases and controls respectively. 
  
Presence of C allele was observed to be a risk factor for T2DM, where as the T allele exerted 
a protective effect against T2DM in our population (p<0.05). Presence of C allele was 
directly related to higher BMI, WHR, dyslipidemia and uncontrolled diabetes. The Arg64Arg 
was rarely present in our study. Similar results were observed in Kyrgyz population 
(Mirrakhimov et al., 2011). Our study is in accord with some studies that show associations 
between Arg64 variant of the ADRB3 gene and early development of T2DM and decreased 
early insulin response to glucose load (Walston et al., 2000). Some studies with cellular 
transfection had shown an association with decreased glucose dependent insulin secretion 
(Perfetti et al., 2001). Approximately half of the studies found a positive association of the 
Trp64Arg polymorphism of the ADRB3 gene with obesity and IR (Kadowaki et al., 1995; 
Walston et al., 1995; Widen et al., 1995; Kurabayashi et al., 1996; Proenza et al., 2000), 
whereas the other studies did not find any relationships between the presence of such 
polymorphism and obesity, T2DM (Awata and Katayama, 1996; Gagnon et al., 1996; 
Oeveren et al., 2001). Such discordant results may be partially explained by ethnicity, age, or 
population differences in studied samples. 
Almost invariably, discussion of the current diabetes epidemic engulfing both the developed 
and now the developing world includes reference to the modern “toxic” environment. For 
many of us, food has become so plentiful (if nutritionally suspect) that overfeeding on empty 
calories is all but inescapable. The preponderance of sedentary activities has transformed 
physical exercise into something that must be scheduled as opposed to an unavoidable burden 
of daily life. The result is an obesity epidemic paralleling, and contributing to the diabetes 
epidemic. The “thrifty gene” hypothesis has proposed a survival advantage to a fat-storing 
phenotype among Paleolithic populations. Persistence of that phenotype could predispose 
certain groups and individuals to weight gain and T2DM (Prentice et al., 2008). This study 
and its findings may be useful and provide some basic information regarding our 
understanding of complex pathological interconnections between metabolic heritage and 
modern environment. 
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Appendix I 
Materials used   Source 
Acrylamide Sigma Aldrich, USA 
Bis-acrylamide Sigma Aldrich, USA 
Agarose   Sigma Aldrich, USA 
Ammonium acetate Sigma Aldrich, USA 
Ammonium persulphate Sigma Aldrich, USA 
Chloroform Qualigens, USA 
dNTP Mix Fermentas, USA 
EDTA    Sigma Aldrich, USA 
Ethidium bromide Sigma Aldrich, USA 
Ethanol Merck 
Glycerol                                                                             Qualigens, USA 
Isopropanol   Qualigens, USA 
Isoamyl alcohol                                                                 Qualigens, USA 
Markers (100bp)                                                Fermentas, USA 
PCR buffer                                                                        Fermentas, USA 
Phenol Merck 
Proteinase K                                                                      Genei, USA
Restriction enzymes                                                          Fermentas, USA 
Sodium acetate                                                                  Sigma Aldrich, USA 
Sodium hydroxide                                                             Merck
Taq DNA polymerase                                                       Biotools, Spain 
TEMED                                                                             Sigma Aldrich, USA 
  
APPENDIX II 
Preparation of reagents 
1.  Tris buffer (1M) 
Tris base    121.14 g 
Deionised water   800 ml 
The solution was vigorously stirred on a magnetic stirrer to dissolve the contents and the 
pH of the solution was adjusted to 8.0 by adding - 42 ml of concentrated HCl. The volume 
of the solution was made up to 1 litre with deionised water.  
2.  Na2EDTA (0.5 M: pH 8.0)  
Na2EDTA    186.12g 
NaOH     ~10 g 
Deionised water   800 ml 
The solution was vigorously stirred on a magnetic stirrer to dissolve the contents. The pH 
of the solution was adjusted to 8.0 by adding NaOH pellets. The volume of the solution 
was made up to 1 litre with deionised water.  
3. Erythrocyte Lysing buffer  
1M NH4Cl                                      15.5ml 
1M KHCO3                                    1ml 
0.5 M Na2EDTA                            20µl                                   
Deionised water                             80ml 
The volume of solution was made upto 100ml with deionised water. 
4. Saline EDTA (SE BUFFER) 
 5 mM NaCl                                  3ml 
 0.5 M Na2EDTA                          8ml 
 Deionised water                           80ml 
 The volume of solution was made upto 100ml with deionised water. 
5.  Proteinase K (10 mg/ml) 
10 mg of Proteinase K was dissolved in 1 ml of deionised water and stored at -20oC in 
aliquots of 1 ml each.  
6. Tris-saturated Phenol 
500 g of phenol was dissolved in 500 ml of 0.5M Tris (pH 8.0) and 8-Hydroxyquinoline 
was added to a final concentration of 0.1 % and stirred on a magnetic stirrer for 15 
minutes. The phases were allowed to separate and the upper aqueous phase was removed. 
  
The procedure was repeated thrice with 0.1M Tris (pH 8.0). Then equal volume of 100mM 
Tris (pH 8.0) was added and stirred to emulsify, phases were allowed to separate and the 
upper aqueous phase was removed. The procedure was repeated with 1X TE until pH of 
upper, aqueous phase was less than pH 7.2. The phenol was stored at 4°C in a dark bottle. 
7. Phenol:Chloroform:Isoamyl alcohol  
Phenol: Chloroform: Isoamyl alcohol (25:24:1) reagent was prepared by mixing 25 
volumes of Tris-saturated phenol, 24 volumes of chloroform and 1 volume of isoamyl 
alcohol. The solution was stored at 4°C in a dark bottle. 
8. Sodium acetate (3M: pH 5.2)  
Sodium acetate.3H2O               408.1 g 
Deionised water     800 ml 
The solution was stirred on a magnetic stirrer to dissolve the contents. The pH of the 
solution was adjusted to 5.2 with glacial acetic acid and final volume was made up to 1 
litre. The solution was sterilized by autoclaving and stored at 4°C. 
9. DNA storage buffer  
1 M Tris        1ml  
0.5 M Na2EDTA    0.02 ml 
Deionised water    80 ml 
The volume of the solution was made up to 100 ml with deionised water.  
10. TE (lX) 
1 M Tris base                10ml 
0.5 M Na2EDTA    2ml 
Deionised water    800 ml 
The volume of the solution was made up to 1 litre with deionised water.  
11. 50 X TAE (pH 8.0)   
Tris base     242 g 
0.5 M Na2EDTA    100 ml  
Glacial acetic acid    57.1 ml 
Deionised water    500 ml 
The volume of the solution was made up to 1 litre with deionised water. The solution was 
sterilized by autoclaving and stored at room temperature. 
12. 1X TAE (pH 8.0) 
50X TAE      20ml 
Deionised water    980 ml 
  
13. Ethidium bromide 
10 mg/ml Ethidium bromide was prepared by dissolving 0.1 g of Ethidium bromide in 10 
ml of deionised water. The solution was stored in a dark bottle at 4°C. 
14. 6X gel loading buffer 
Bromophenol blue was dissolved to a final concentration of 0.25% in 40% sucrose 
solution in deionised water and stored at 4°C. 
15. 30% acrylamide 
Acrylamide     29 g 
Bis-acrylamide   1 g 
Deionised water   50 ml 
The solution was stirred on a magnetic stirrer to dissolve the contents. The volume of the 
solution was made up to 100 ml with deionised water and stored at 4°C. 
16. 10% ammonium persulphate  
Ammonium persulphate  0.1 g 
Deionised water    1ml 
The solution was stored at 4°C.  
17. 10X TBE (pH 8.0) 
Tris base     108g 
Boric acid     55 g 
0.5 M Na2EDTA   40 ml 
Deionised water   600 ml 
The solution was stirred on a magnetic stirrer to dissolve the contents. The volume of the 
solution was made up to 1 litre with deionised water. The solution was sterilized by 
autoclaving and stored at room temperature. 
18. Formamide gel loading buffer  
Deionised formamide  4ml  
0.5 M Na2EDTA    0.01 ml 
1.5 NaOH     0.033 ml 
1% bromophenol blue   1.25 ml 
1 % xylene cyanol FF    1.25ml 
19. Gel fixing solution 
Ethanol    100 ml 
Glacial acetic acid   50ml 
The volume of the solution was made up to 1 litre with deionised water.  
  
20. Staining solution 
Silver nitrate     2g 
37% formaldehyde                     0.75 ml  
Deionised water            600 ml 
The volume of the solution was made up to 1 litre with deionised water.  
21. Developer 
Sodium carbonate   30 g 
37% formaldehyde   0.5 ml 
Na2S2O3.5H2O    1 mg 
Deionised water    600 ml 
The solution was stirred on a magnetic stirrer to dissolve the contents. The volume of the 
solution was made up to 1 litre with deionised water. 
22. Stop solution 
Methanol    500 ml  
Glacial acetic acid              120 ml 
The volume of the solution was made up to 1 litre with deionised water.  
23. 5X TBE 
Tris base                                    54 g 
Boric acid                                  27.5 g 
0.5 M Na2EDTA                         20 ml     
The solution was stirred on magnetic stirrer to dissolve the contents and final volume made 
upto 1litre with deionised water.     
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